Advances in Cancer Treatment

がん治療のあゆみ
2018/第38回一般研究助成

38

公益財団法人 がん集学的治療研究財団

! # "
éV

?

¼

¡

p

ÂÜP~0:aøYë¹©ÜPQ":aPøYëOD]¹©`þ5þD]L«O"?^OD]5P`±:Pr`Ë5"ðOB<IðPVëÃ`Z\ÃYOî¿D]ë
~`B"XHJÒP¶ÈPÅ(OÍ¸D]?L`YLBJ"+32*j&"¡//j'O;A^T

BF!
ÜPPòNé­LBJ-Iª>[^TD!+IQ"Eæ;«b!¹©&JFMC ¹©'PîæK":aPë~OI5JEæ;«b!¹©`?^TK/+ B"îæBJ;TBF!,IQ"ãÂÌÖP×K"Âé­P}LBJjËHJ8\TD!-I:"}n¹©Pþ5K":aPøYëOD]¹©`}n9[{øB"+ÕP("þ5¯`þ5BJ5TD!
ÜPQ"+32*jP;^ü9["}n¹©þ5é­`áB",*+2jTKP-3jKÐ±,"-23µP{`ô="}n¹©>Êx~K½ùO+ÕBF³".31µOGBJ"A0/"+0*Pþ5`Ë
HJT5\TBF!G&LQ"!

:kLN\6](PøYë)OD]¹©K"?^OD]¹©"FL7RðPtN`²¾D]FWP¹©"ðOB5v~"ÀâP·Þ"g%q|PÉR"®5ÿZ:¤HA^]£@Y¹©"NMP¹©XT^J5TD!
i8g=BTBF(:aëPyU-2Ï)Q"w5,3j]ô'ðP¹©5P|ÑKD!

{µ3.2µPS9[½>A^F0µPô'K4\"5E^X_:ÒjhntosPØ<OP¹©KD!G&B¢X*d"z"JU""¢"m"lLEÙK"êIOCBF¹©hK¬-5³:e[^J5TD!
ßâQÜP:+32*jP;^ü9[áBF(}n¹©þ5é­)Py¨`Ç<öQD]¦ùN|Ñý
KDPK"@ÎW=^RÆ5KD!
A[O"^ÜPLBJQ"ÓTKîæBJ;F!çºP[)|`XLOBJ"i%fo%e&DB'é­`Ë6?L`±BJ5TD!ÝÓlhdi%f:TA^J5TD:":av~P DB QfOùNïYbumrP6oLN\"?Pé­Q",*+2jPÄ8a$!Ãi%fo%e6oé­LBJÚMA^TBF!
fO^ÜPOQ"JUPzþ~OB Phase vçº`W+,"***w(P[)|:àA^

J8\"?^`}»YO DB D]?LK"xÒYx:ÉRBJ5] ACCENT i%fo%e&³Uzþ~OD]xÒL÷P!çº DB'L`ÐBF5LÊ7J5TD!!çºP[)|`

5FJ¥i%fo%eKQ"#3PEALhP7A`89B"cukpbujPF^4Y"jY0óOZ]vPÃP{5NM`%ÛO:D]?LK"_:ÒLxPJU:8vYObC
NP9"{6P9L56VjPLO_7:û]PKQN59L¤HBJ5TD!
ØÀO"w5-*j]P}n¹©þ5¯õ'íOQÜPé#~">ÊXK@1W;TBF>Êx
~P<8}OX@9è\TBF?L",Z\ñ.B(>TD!TF"@úì`è\TBFÂÜP~
0:a¹©ssVPÔu<8OQ",9[PÁ`.B(>TD!^F¹©`2/D]ô
'ðP}$"@2=5FG;TBFæ;IqðP<8}"E<P}$P\`"ðAa`K}OÊ7]:aë"ÂO°>JË=^RÆ5KD!ÓÀLX^ÜPSP@å"@äc`è\TDZ6"D§
B<85.B(>TD!
w5-+j-´-+i

%

#

"

!

&

$

^Ôwµ[_h

µ[_Ä

l

Â

u



µ|gVnÀG6ß§9¦4L:!
¼¥f¿E9C"ð£aé1dÑEFR.S$qHkÈî%Gp:SwVÞ9"*'HaÞV
Å2L9>!aÞÇM°RI,('ÎD"·CHaÞ¡ñHXY#VäzPR·CHµ[_Gº×9"¶ÖbV9C->?2L9>!=H¶ÖbDI"²¼ÖbHK0GÖb1ÛQF-P.ÖbÒØ
VÆM>¹¼ÖbDÊV/r-9C/RL:!=Hµ~eVäzD}9"xS'&)ÎG¾)(i^Ôwµ[_hVj9L9>!µ[_1¦Z0Q^¿;BtôVØGAC"­GÖbV
-L9>!5Hµ[_htóI"ÚªvJÌæªVí9"|]OëèVsó9"Ü»9C/RL:!
=H~e"+HaÞf¿V¢«¼¥ÝE9CëhG¦§9"¤ÏÅ2L9>!
¢«{Vï7TS³®àG/r-9L:!
ÃoßEFS0N9TL<W1"'Ð

HâÉGCw~eVÓÕ9C->?2L:!

L>"wôÙVÓÕ7TSGI$1WkÈîwÁ¢«{%HÝ¢VÍ>Væs9CÅ3
P./r-9L:!³®àHy¯GcUSEENG"Á0QH¢«{1qHîwGçì@"hG9C-SNHE©9C/RL:!âÁI`á¨D:HD"acknowledgement V×9>ôÙV
m->?35EI"êF\ãVAC/RL:!

GFRL9>1"¢«7TS+åH³®à"iIâËG/MDE.68-L:!L>5H¸¬Q

9-³®àV6©´->?2L9>±½ÕH³®àGN"3/ò§9¦4L:!

" & ( * # ! % $ )'f¹z $$$$$$$$$$$$$$$$$$$$$$$$$$$$ Ô² ¥ y j Â¤s]É $$$$$$$$$$$$$ XÀxq¤TY^"¤TY² d ® o %©gV167

gi1ª-7µØµZb«¯ ¶ $$ !

5AG0M)
C-1!F=/.

%u±ÑÕ DNA 8Ò'.½i|ÁiW2w1h-7xq| ¸ ¨XÙ $$ $
?W:XH+M)
K#$!;31M%'&"% IDH& ÈU)p4 - DNA ÅmÈ[2_Ì0°1
l/*nØË2a¿%[ki1(+7@:G=:RA?IQ2m¼_

Ö ¡v

Ð $$ !!

,N@XG0G0)(094.
JD8/.0<>­ ~» $$ !$

6Y2BG0(0P
LEQ0!U*0%ÚÏÓu±ÑÕ DNA 8Ò'.P>FHJ:<MA#2t\1l/*¢Ã¼"¢r`Ûi1ª-7c´Ø2{Ç[325%e¦S³}\8Î-7P;NEÍ@ODCQL9KPBR8
ÆÒ,.!ºi1ª-7nÊ£Ø2a¿¾¬

Ä $$ "!

ITG0G0)(0794.
C-1/.0RV§ ·×Ì $$ "#

5AG0M)SOM)/.

? c Î V R 9 [ W

1/0(%-"#$.*()"1!$+3,43&'2
#á

(%

+.

£QúF_ ãR*8!¦ØQ¡EMåIPu&h&R03?¨ûD`M:I!Ç´"LMR(y{r«ÿ«;)?£Ó~J®bEMÒZç,OæA¡aKM:_6ë?ÏÅD`I!Fº¬SÈE£QúF_îùã

64"n=8/)¶SÂ MLR(,1#64"n=015)¶Q;E MELD ljdZbÌÁEIßX105XbúàOEI!& MLR(*1#£¡YÒZu&h&"?ÂA"?S)vxp¦ØßXYMQøA¢cN:I!ã¾45HÆ7î÷TSÂ MLR
2-=\U84#
5-N9KI!VIvxp¦ØßX(n=61)NR"ã¾45HÆ7î
¶=\U& MLR ¶NG`H`60#
1-=\U33#
7-N9^"& LMR SÇY×QPÆ7¤»ÊR÷TSÂ MLR ¶=\U& MLR ¶NG`H`74#

LN9

KI!VI& LMR ¶NS±ÙQ=:MY CD3'CD68 RëÈE;?&"N9KI!LMR S£Ó~J®b9F_Ê
N9^"îù ãQ\_çÁ £QúF_Í*ÎV*ý>QMPPÊN9_!

# ! $ "
088/5ü$¨VN"£QúF_ãìïS45î÷TN2/-ò¾O²XM@WN9^/ÎVSôú

)³§9_:S¦F)Q@*N9_OÀ<]`M@I?"08855Q Mazzaferro ]0)Q\^DÄD`I
vxp¦ØR03S"£QúF_

ãìïbÑ¼F_CO?6N9_CObêQÏEI!E>E

P?]"ÒZR½éOý@DRWNSã¾Æ7qeyli¶RÚSONSPA"G`]AS)Ë=Q<MÒZu&h&b¢XI*¦Ø?DÄD`_QÍKI!%SÒZ·,4cm >L PIVKAII,
2//mAU'ml RßX}R£bãR*OF_µý¦Ø1)bDÄE"ÒZu&h&bñþ¦ØQ

<_CONîA)|ë.bÀUE"Æ7ßXb\^íQNöF_CO?6N9_CObDÄEI!
Kaido ]2)YÒZé0/½}2>LÒZÇý·+4cc >L PIVKAII+3//mAU'ml b

£QúF_

ã

*¦ØOF_­-¦Øb(ÛE"GR¦ØNSGäÕZ&BßXbÚF_COQ\^"W¿Pìïb1_CO?6N9_ODÄEI!E>EP?]"áª¦ØQ:MYVI

ã¾Æ7ßXS÷ÉE"ãQ\_ÎV©bÚD`IßXR÷ÉY:'SN@P:â°N9^"AS)Ë="ÒZu&h&QLBåIPË=R703?¨ûD`_â°N9_!</¦ØSã¾£Æ7bóQNöN@_YRNSP:!Ç´ Yang ]Q\^"LMR(lymphocyte monocyte ratio"y{r«ÿ«;)?
3)£

QúF_ðÚ¾Æ7Q¯A¡a_ÊN9_CO?DÄD`"ÒZÓ~R<ÜJ®?ÒZR7Oç,D]QSÎV¾Æ7OæA¡aKM:_6ë?ÏÅD`I!£Ó~<Ü®Q%KE"GRLO
ã¾£Æ7R¡a^Q¡EMI]>QF_COb¸EI!
'&Fº¬S088656¹>]1/0754¹VNQµÔýÞ¥$õÃQMîù
ksf{nR;J"?S)QãbÌÁEIìèz

ÈE£R÷É?I]>OPKI105XbúàOEI!

ãR*S"ÒZ·,4cm >L PIVKAII,2//mAU'ml RßX}R

£b

£QúF_



ãR*OF_µý¦Ø OE"vxp¦ØßXQúEMYÖBPe{tg&woj{m{nQMÐ7)/?1]``T
2)

C»*NS9_?ÎV*OEI!óMRîù
.µÔý? Þ¥$õÃãßXSµÔýã*QMÝ4D`

pcCIK|prC=K§

2

½§gl

>¿A8K!
!

"53"n=/04'B¤ LMR
prC<@pcL|?>`RZNbT¿L"} LMR u&,0#
u&*0#
53"n=7.'D0uC±;"¾°»n¦«wd:IF"¼L­m<>!G>®´&n=/44'C:9@"_bYt&CD3'B\Oa[M$S&CD68'L¶ehnC@y<"LMR¢BDqÁL¯i<>!{Cc{pr¬¿C:;K·{dB<@D LMR D¯iH©¸C|?
>!¨x¢E£f¢L¹9"¨xn¦³B<@ Chisquare y¥"KaplanMeier ³:IF Logranky¥"Cox ­¿XQ$Uy¥L¹9>!
@! 5 LMR 3#)(= LMR 30%'D7AC.>,6'?-

(

,

¾d
`RZNbTªÀ&'`RZNbT²&¡%'
UV$ªÀ&'~ºP^[T
GV%SLV&-'MELD Score
Child Pugh C
HCVAb&('
AFP&ng%mL'
PIVKAII&mAU%mL'
Âv&cm'Âz&z'j¦]^Wsk°»n¦d
Âv&cm'Âz&z'µo8J°»n¦]^Wsk* LMR )
!n=$%&"

1 LMR )
!n='#"

p0

36&0/)51'
47%35
13&0.)40'
53&37#
3-'
2/#
.&04#
5)45#
4'
/0&.)04'
45&31#
0-'65&47#/-'
026&0)6.55'//4&1)/706'
0#.&.)4#
4'2&.)/..'
15&07#
2-'

35&2/)54'
33%13
14&0.)40'
26&31#
1-'
2.#
3&01#
4)35#
2'
/3&0)11'44&51#
1-'
40&46#
7-'/420&/)21/.5'
360&5)/147/'
0#1&.)5#.'/4&.)2..'
13&16#
7-'

.#
04
13
.#
53
.#
21
.#
42
.#
*.#
./
*.#
./
76
.#
./
.#
*.#
./
/6
.#
.0
.#
/2
.#

0#
/&.)5#
6'4&.)//1'
73&53#
2-'
3/&2.#
3-'

0#
3&.#
0#
5'
/7&/)216'
4/&45#
6-'
32&4.#
.-'

.#
./
.0
.#
0/
.#
*.#
./

@" /2&<$*9;/+84'9:&1B$*,6(,ªÀ&+4.'²&¡'
HBsAg&('HCVAb&('Child CMELD score&+0.'
AFP&+3..ng%mL'
PIVKA II&+/..mAU%mL'
Âv&+1cm'Âz&+2'
¤±h
µo
53'
} NLR&,0#53'¤ LMR&*0#.-/Odds 3
/#
445
726
0#
66
.#
/05
.#
530
.#
547
2#
702
.#
.70
/#
./5
/#
457
/#
732
.#
11/
0#
4551
.#
600
2#

p0
06
.#
.1
.#
66
.#
/0
.#
37
.#
./
.#
65
.#
63
.#
74
.#
05
.#
7/
.#
.6
.#
3/
.#
*.#
./

4+2-/
Odds 3
p0
07/
/#
7/0
.#
56
.#
333
.#
153
.#
.57
1#
506
/#
721
/#
7.4
/#
054
0#
555
1#
43/
0#
622
0#
/06
2#

46
.#
65
.#
62
.#
3/
.#
/3
.#
0.
.#
14
.#
1/
.#
0/
.#
/4
.#
.2
.#
/6
.#
/7
.#
.0
.#

; Z  ß L 6 T P

"

3

!

20"n=,-1'I¼ LMR &(-#20"n=4+'|K9>Wâ¾9UNÊÜy¾nL
 LMR &)-#ÇxYFEt"¼ MLR M MLR KÇA MELD score&,0vs.,-"p(+#+,';="Child C
ã&2.#.* vs.0.#-*"p(+#+,'Y¶=~P"° AFP&,1/-ng%mL vs.-/3ng%mL"p=+#+,'"pIVKAII&03-mAU%ml vs.,,1mAU%ml"p(+#+,';="u³¥¸¡Lä¨&,1vs. /"p(+#+,';¿
y¾KÙkK¶7?I;×V:IJFE!mÒu³¥¸¡Lä·

6W7Mefaw

ãÇÝKMÙkMÂRJ:FE!OEÊÜy¾nK}AGM"¼ MLR M MLR KÇAÊÜy¾ä
&-#
0cm vs.-#,cm"p=+#+,';·<="ä¨&,4 vs. 1"p=+#+-';¶="Õz¤ÝKMÙkMÂRJ:FESLL"ÊÜy¾efaw

ã&1+#+* vs./+#
0*"p(+#+,'YÙkK¶=~

Q?I;×V:IJFE&§,'!
l¢0ÃÖÆ«µÝM MLR 9UN¼ MLR HCXDX2,#.*
9UN40#
1*&p(+#+,'"l¢0Ã«µÝMCXDX1/#
1*9UN4+#
2*&p(+#+,'H6FE!OE
efaw

ã&n=2-'KFGv¬BWI"l¢0ÃÖÆ«µÝM MLR 9UN¼ MLR HCXDX30#-*9UN//#
3*&p(+#+,'"l¢0Ã«µÝMCXDX31#,*9UN.3#/*&p(+#+,'
H6FE!@VKefaw

ã&n=2-'K9>WÚ½nK}AG¶Ñáv¬Y8I"±«µÝK}AGM¹©&Odds Ç -#4/3"p=+#+.'"MELD `^\&Odds Ç /#214"p=+#+,'"¼ LMR
&Odds
Ç /#
3--"p(+#+,';g`]nIAG"OEÖÆ«µK}AGMÊÜy¾¼ÐpªÐL~Ù&Odds
Ç .#222"p=+#+/'9UN¼ LMR&Odds Ç /#,-3"p=+#+-';g`]nIAG»@X"¼ LMR&(-#
20'MÀÞÚ½nH6W?I;×V:IJFE!OE" MLR &n=44'9UN¼ MLR
&n=12'K97G CD3 9UN CD68 LØo¯£KGCXDXäÁ5Ó¨9UNd]hc[$_¨
YÉqBWI"¼ LMR HMK97GÙkK CD3 Û©Ó;J=&p(++,'"CD68 Û©d]hc[$_Y¶=~Q&p=+#+.'?I;×V:IJFE&§,'!

8$ 5 LMR 4',+9 LMR 4)'(-7<:* T 6;"%#',+2/31.!0"&#{l¢L{ÆM-1ãKÂR"ÆÍjMÅ&n=4'"gib®&n=1'"&n=0'"{´&n=/'"ÏÔ&n=.'9UNÎ¦&n=,'H6FE!Æ
9UN..#-*H6FE&§-'!Æ/0#
4*I"­ËÄãL0Ã9UN,+Ã«µÝMCXDX.3#3*

ãLºHSÆÍYws¾­rÄH6FE

ãL0Ã«µÝMãL0Ã«µÝM+*H6WLKÇA"ÙkKàH6FE&p(+#+,"§-'!

ÆL«µK}AGM"Æ AFP).++ng%mL&p=+#+,'"¼ LMR&(-#
20'"ws¾Æ²L­
JA&p(+#+,';ÌLg`]nIAG~OXG7E&È.'!

4ÓÜwÉJRUÎ¬JÝAU¶æ·&æ}ß=# 46)D(-3.?7*9F8@CI!%"',+9F)D(-21EB;*>A!&"
G$ 4/<8469F8*@C)5H(-0:

&

'

!+(),
"%
$#

p*

03#
0
0
//#
1
1,#
/4#
.1
,
0
.4#
0
/-#
2
0/#
/
//#
0,
,

,#
15
21
,#
5,#
00
,#
04
,#
,,#
,,#
-.
,#
*,#
,54
,#
,5
,#
*,#
,-

mqi¿î
¼ß¿îãõ~¡ôåÊ½
öÂ~&ù
[td%k\stAFP'°ð(+/,,ng&ml
PIVKA'°ð(+/,,mAU&ml
31
LMR * .#
Ù°ð
wÉ¦-ïuîK°ðå°ð×ÔÃ

1/#
/
2
1/#
3
01#
3
-5#
/
.3#
/
1/#
,
,
,
2
..#
.
-.#
3
0-#

"

!

¤²NF#$IJÝAUwÉæ}ñá¿;÷®?VE<C;"BVSKMGYHK«Ò$ÕL"»)"»)¥Ï"B@E»)l%]%F«Ò?VE7C!ÓÜwÉFL"©IÓÜfg%Xfg%
JAUG78OErb^K­7íºI$Õ;"@E7UCO"RT£F<UR8Iyµ;ûNVE7C

J°ð6U7Ló°ðX!Ú

!¯þS:J@C LMR L"»)KôÄJ9=U¾¹yµG-()/(

787NNFJI7Ë@7é:S»)Kë§X³6U7L!ÚAUl%]%F6T"BKvJ@ELóÇJÞ?VE7U!
»);´ÒAU`[e][tQ_p][tLÁK|ÅX¸AU>GJRT»)KÎçXÂ=U;"
BKxøF»)JÌÀAUrtjLª»)åJê<"?SJrt»)Kª¢ÑXÑ~AU>G;÷®
?VE7U1(!NCJrtj;¤Æ@E7UÈLK°ðJ"AU>GP÷®?VE7U2(!
üFL"ÁKrtjl^skZ%aòLzâKìòGóÇJ'¨JØ@E9T"zâK

LMR KÚä;ÁKX!ÖF<U>GLóÇJýÍ7!zâJÛ²AUàL»)(l^skZ%aJõ~AU>GFKðÓQÎçèwJWDE7U>GPþS:GIDE7U3(!BKo]
hcnJ@EL"»)(l^skZ%a;»)±úGGPJ PDL-X@Eÿ{±úJÝ@E%Ð
åJê7E7UG78÷®P6U4(!

3 C ] r < 0 ? >5! $ # "
UV;g58UL`[Yd<HEGDIFXO;14A LMR ="pK;eiRk27UV;14AV^Jm_TWBlN6ARkbBo6AMZ90A!LMR =cfUL`;@AaYUV;g6A\j]rjPShnQ;oq:MZ90A!
&%'%Mazzaferro V, Regalia E, Doci R, Andreola S, pulvirenti A, Bozzetti F, Montalto F, Ammatuna M,
Morabito A, Gennari L : Liver transplantation for the treatment of small hepatocellular carcinomas
in patients with cirrhosis. N Engl J Med 334$,/)/"'//,#(%Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y,
Sugimachi K, Kayashima H, Iguchi T, Maehara Y : Impact of desgammacarboxy prothrombin
and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 87$+)'-"(&&/#)%Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, Takada Y, Uemoto S : Usefulness of
the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 154$'&+),&"(&')#*%Yang T, Zhu J, Zhao L, Mai K, Ye J, Huang S, Zhao Y : Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammationbased predictors of recurrence in patients with
hepatocellular carcinoma after hepatic resection. J Surg Oncol 115$-'.(."(&'-#+%Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T, Ji L : The prognostic value of tumorinfiltrating lymphocytes in hepatocellular carcinoma : a systematic review and meta-analysis. Sci
Rep 7$-+(+"(&'-#,%Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S : prognostic value of preoperative
peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery 139$-++,*"(&&,#-%Nagai S, Abouljoud MS, Kazimi M, Brown KA, Moonka D, Yoshida A : peritransplant lymphopenia
is a novel prognostic factor in recurrence of hepatocellular carcinoma after liver transplantation.
Transplantation 97$,/*-&'"(&'*#.%Kuang DM, Zhao Q, peng C, Xu J, Zhang Jp, Wu C, Zheng L : Activated monocytes in peritumoral
stroma of hepatocellular carcinoma foster immune privilege and disease progression through pD-L
1. J Exp Med 206$')(-)-"(&&/#

6±%V_ DNA UX2A:¡Ü»?ß¡ËI²ÛH

?S³ª,479 DNA '8!#
5*2/63*(0%-1$)"&.+
»1

üh)

+& :¡ÔÜEJ6¢+H:¡UóHðÞ?S7"µ?¬+H:¡7Ë?S9ë71S!N³ªEJ";IP3Gý5IÕjË1S2J?ß-IúÅU¿/Eè"?SJKI;UR+F=A!¶;õI.ÍF~ïU½2"¶;õFö3I.ÍF~7±%H²Û<TAãÀ"circulating tumor DNA F<*="@I°Ï+FUï=A!
Ü»H ctDNA 7²Û<TAáeJ"»7"óeÂ;U8NA!ÜòH ctDNA 7²Û<TAáeEO"Ü»H²Û/}FGBAãÀ"Â;G9"'¤îú79E1BA!Ü» ctDNA J¿/IÂ;Wù ÍE1R"NKEJÙ[Idà+Â;è"%÷"Õjs$\$&PRO­NDô¤I#EÂ;IWù79E1BA!

$ ! % #:¡ÔÜ»IÂ;J"NMEÔÜUÖ:AÒóýIS,*(H;î=D2S!N³ªEJ"Ü»HÝ
aKI¸EaUÑ·?L9"±% circulating tumor DNA%}"ctDNA&UX2DÂ;¿xd_®UÜ»ô¤H<*?S;FUR+F=A!MA"ctDNA UnY[s$\$F=D\X="Ù[IÂ;è"KPRO"¿/"G")æØGè"KU¼$?S;FUR+F=A!
('")*
0E:¡ÔÜUÎ½="B^B¤ IIIA E1BAÒUþâF=A!Ü»HÝaKI,J¶ø
F=D:¡èa]YlwY|HÙ2"Î½ITQHPR"áeUÞ=G6BA!ðÞUÎ½=A:¡áe6Q¶;õUÃÓ=A!¶;õIrysx|º*owpX|IO@N6Qz$b$^uqiu$s
Y_{hYe_cv|KHPR¡ÄLU×="DNA U&Û=A!:¡g.,.ÍIóZ_f|c%/P0*-/WtmÊ&Uï?S Assay ¯U in house EÆì="DNA ²ýUÐêÿc$_Z|dïH«=A+&',&!J"npX$a$kU[ DNA 6QîåÄL¯fF~U8=A34E"±iU[I DNA
6Q7VIýÄLF~U!Ç=A!:¡¶;õFö3I mutation U ctDNA F*¨="@I°Ï+éUï=A!N³ªEJ"PCR Zw$"c$_Z|dZw$Eî>S>4~+GF~%¥Yë&I²Û
UZ4"ÕjU[I)C/F~I¿/²ÛU9F?SDÍn$a$jX|`§ÜUÌX=":¡4~+G ctDNA U²Û=A-&!
ÜòH+"Ü»J,¦[EÃ±U½2"±íÕjs$\$5PK ctDNA Uù*=A![èaE(äIdà²ÁU½2"Â;ITQHC8çÚH°È=A!ctDNA HPS?ß¡ËI²Û9UA
?SAN"}IA¾RUñ*=A!
!&ctDNA ITQFÂ;TQFIö"&Â;Wù

ÍH?SûFbï#&Â;áeH52DJ"°Ï+GWzyC/IéU²2="Â;78E8SÏ¤H
Õjs$\$"ctDNA I,®E=²2)É]´`%B :7V#¹©£Be|g$=D"÷"

: M h  F 6 J H

"

7

!

Y IIIA FXVi10LS{sC<?!10"-,E87An}e^_B ctDNA L_
m<?!ctDNA _m[C ctDNA _m[BVi$k

FLT=KC""y"ZQ"jnch"~v\"UWxoF"pRUgaFEPdLID9@?:"k]G ctDNA _m[BPE;9@?'-fr(!
<! 68 ctDNA 15&?>%+"$-4:0

Number of patients
Male/Female
Age
Smoking habit
smoker/nonsmoker
Tumor size
Surgical curativity
curative/noncurative
Histology
Ad/Sq/others
Pathological vessel invasion
present/absent
Pathological lymphatic invasion
present/absent
Adjuvant chemotherapy
performed/not performed

Preoperative
ctDNA!"Preoperative
ctDNA!+"

p value

00
/0&-,
0*-#
4
24#
.4&-2
1*0#
3
/1#
0-&/
.4&-0&.

-,
3&/
2*0#
,
21#
2&0
1*-,#
2
02#
4&.
2&/&-

)
NS
NS
NS
,1
+,#
NS
NS

.,&.0

1&1

NS

..&..

2&0

NS

0-&/

4&.

NS

<! 2;%*/(.'#)3&9=@,7Variables

HR!%$#CI"

p value

)3,
3-)4,
4-)

-'Ref.(
-#
,4',#
/0)3#
/2(
-#
..',#
12)4#
/-(

,#
311
,#

y
qy
ZQ'ref#ZQ(
~v\
|X
tX
>F
k ]'mm(
)/,
/-)0,
0-)
UWwln`k O%N%zubn` ctDNA_m_m-'Ref.(
,#
52',#
04)3#
54(
-#
12',#
2-)4#
10(

40
,#
30
,#

-'Ref.(2#50',#/0)-2/#
21(
/#
,1',#
,1).51#
,3(

2
,#
.
,#
15
,#

-'Ref.(
-#
-.',#
/5)3#
44(
2#
,1'-#
,2)./#
11(

43
,#
,/
,#

-'Ref.(
-#
,-',#
//)4#
25(

52
,#

-'Ref.(
-#
00',#
/3)2#
2,(

12
,#

-'Ref.(.5#
4'--#13)25#
0-(

+,#
,,-



y

8

a DNA N/9[tdv[TkBbsAZ7Kc]t ctDNA bs^%n=('&B"+=tdG ctDNA Nbs6"+>Gi69%{(ABjx&!k)=C"td(*Qf"ctDNA Cbs5L8")>Gi~=.K%{(-jx&!
iyA0/<"rBq

P#O#%CEA"SCC @?&C"tdA}zU7Ky2

1;92"

ctDNA AZ6<C"tduWB%td('$,'&=Gt>DEBg=.;9%{(AB jx&!F9"wAi2X=3KAmKF="allele fraction%Tlh&Ct>DE
MI8"gNSn7K_e2.;9!7@M:"tA ctDNA Nbs69Yp=C"ctDNA B|
RN`7K4>AHJ"td\AiB2V=.K4>2o5L9!
!

"#&! ctDNA "$%('#

9 c Å P Q 3 Z W

9Ðê ctDNA ¨ÏQHDP[]"D¹/åób4¨(C^M"ctDNA ¨Ï¥LR"HxPI±
98QL3IF%à,2¾Ö&!VF"Ð± ctDNA ¨ÏQHDP[]"D¹/åób4¨(C^M"ctDNA ¨Ï¥LR"ìS9¹/AK7]"HxPI±98QL3IF%à,B ¾Ö&!
Ð±QD¹/åóP¢bUC}ÁbæAFM>`"ÊU¦% p =*#*-&"Ð± ctDNA ¨Ï% p(*#**+&9HxO}ÁL3IF%à,C ¾Ö&!
!

"/# 5,403)(&'1 !$".2 ctDNA *-&65 !%".+ ctDNA *-&65&%.ÉÐ±Q¹/R"CBLÉÐbË<FÇQF-*)P/åAK4^9""$OLÿ~Q#L
RÔ×Ú"ðÑª"ÊUr$f$ØÕ8\¹/bÞúC^Ù¶9ô4!C©
QÎLQÊUr$f$9ô;Q×SLÐ±P!

LR"CEA"SCC ON

AF|@"ctDNA R¹/×SP74KÐ±Y!

EDµübzÃAF!Ð±P9 micro QuptL{¿A systemic disease QÚøL3_S"ÉÐR£ÑPA
Z6"ìõPUC debulking Q²R¯"$OQ8YA_O4!|@"ÐêP ctDNA 9¨Ï@_F×
SLY"Ð±P¨Ï'w

POIF×SLR¹/b,XD"2¬9+#.ÄM@_^ ctDNA Qñ"

P[]"Ð±¤XKîQû%Ð±+*'0**QÄ&&L¹/9äPIñL:^>M9Æ@_F.&!ctDNA
Ré»$O«5¡$%yb3AK7]"CAR"ÎLQ¹/ÞúA[]Y"µ'"="!ÛÌOÞ
úAM®6^/&'0&!
>Q[5P"¹/µshg¥bÐ±îP1"C^>MP[]"Ð±>ÒPAQ°;9-M³
6\_^!@\P"îQ¹/ÞúP04"îQÅP+9-MO_S"ÇQI±"QOL Që
PJO9^8YA_O4!½·"EkelgqdvmíºQRÔKYòPßW".QG9PA
R§$P<AK4^1&!¹/µshg¥PöAKR"Ð±îQû8\EkelgqdvmíºbÀKC^ONQÜFOÅPèOY·±÷@_^+*&!COaH"ctDNA R¹/ÄQ.7øb?$P3AK7]"5Ó¹/QûL"7øPBF6$ÅPb´6S"¹/9«»C^êP¸Å$ÅPbáL:^-â93^!
! $ # "C©

R"Ð±Q¹/Þúb¸C$PëC^>MbxàAK­»Yß´þL3^!·±"ÜFOgs

ofthivj$nbNA".ÉÐÇQÐ±ÅPãçbï¶$PëCT;"@\P×SæbßX"·)FýªbT:AF4M³6K4^!
(
C©

'

P?M4FG:"?Â4FG4F9cÍ$ÅP©

¼ùQJPÈÝAØ=VC!

:BEG DNA 5F/1C8@=DA86>3;?2704<9

10

"

!

&$Goto T, Hirotsu Y, Mochizuki H, et al : Mutational analysis of multiple lung cancers : Discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget 8#(&&(()(!'%&,"'$Nakagomi T, Goto T, Hirotsu Y, et al : New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget 9#&%+(*).!'%&-"($Goto T, Hirotsu Y, Nakagomi T, et al : Detection of tumorderived DNA dispersed in the airway
improves the diagnostic accuracy of bronchoscopy for lung cancer. Oncotarget 8#,.)%)&(!'%&,")$Newman AM, Lovejoy AF, Klass DM, et al : Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34#*),**!'%&+"*$Diehl F, Schmidt K, Choti MA, et al : Circulating mutant DNA to assess tumor dynamics. Nat Med
14#.-*.%!'%%-"+$Chaudhuri AA, Chabon JJ, Lovejoy AF, et al : Early Detection of Molecular Residual Disease in Localized Lung Cancer by circulating tumor DNA Profiling. Cancer Discov 7#&(.))%(!'%&,",$Dawson SJ, Tsui DW, Murtaza M, et al : Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med 368#&&..'%.!'%&("-$Tie J, Wang Y, Tomasetti C, et al : circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8#()+ra(.'!'%&+".$Antonia SJ, Villegas A, Daniel D, et al : Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018.
&%$Forde PM, Chaft JE, Pardoll DM : Neoadjuvant PD1 Blockade in Resectable Lung Cancer. N Engl
J Med 379#e&)!'%&-"

6 _ Ò p M 1 W S

11

IDH! <*"1)$ DNA 6;/2<+(,>&
3894'.%#705?=(-:nô²e(&# #N:\RHL´¨ñI<G IDH* U6 NAD+Âñ$Ú¤½Lª^¦Q<"ÜvÆY@M NAD+(^ü"2L.;@[:I^µá<B!Z´¨HN NAD+MæI°tL*_<"DNA ÞO¤½MFH1[ base excision repair °tMÛihzocÖH1[ PARP MðMuë^-=G NAD+^æI>[jvgysl%TMZ&I NAD ÂñûÈMShpX^ÐSB!AM± IDH* Uê°wÜL42G5ÌU<2LÂñ)Ïð6;Y\B!9QxrwL
42GUbÈShLX[üçº2K»Üvº6ATY\B!¼L NAD+ÂñûÈM«ä7gMBTM microparticle^E<"9QvkwL42G«ä7gLX[»Üvº^µá<B!:\YM± IDH* Uê°wÜL">[5ÌU<2KÒpXMELñ¹<B!

" ! % $
¶EðC{ðÜvH1[ê°wÜNìs6[CÃP<;G2K2ÕH1[!ê°wÜL">[Òp`
qy$iI<G2ÒpLWØöpXI`wbwÈH1[jvgysl%TMZ&MSh6·ÉMKãÒpXH1[!TMZ LX[ DNA d`mzÊ

M O6 }Muiw6UBY> mismatch repair path-

way%MMR&MD'6 DNA ÿå^f:<ÆY=ð^E¢>[6+£2LNÅENJEH1[!RB­
B TMZ M+£7gLXZ DNA M hypermutation LF3{ð3^f:;\[:I6Î1;\G4Z":M45YUèBKÒpXMn6§\H1[!­BM%¥^KRÌ52³8LXZ.{ð6ê°wÜ¦OýEðê°wÜMEòLN IDH* 5ÌMU6¬TGàiH1[:I6Ó;\"×Ç/)'
06Lflz*,+q

M4?øU6ATY\G2[!éóÙYN:\RH" IDH* Uê°wÜM{ðL][5Ì^îLõ®8Gµá<G7B%Arita H, Tateishi K et al. Acta Neuropathol. 2013,
Wakimoto H, Tateishi K et al. Clin Cancer Res. 2014&6":M IDH* UNßËÆY@LVÑ;\"5
FapentUV$ÚðUN{ð3L]Y?Ñ;\[!:M:I5Y IDH* U^K2I<
BÒpN{ð6^`]?ê°wÜMcrKÒpXLK[:I6£#;\[!éóÙYN">ÔLÝn<BîcíMÙdkê°wÜÆY^h2G IDH* UÜvÆYNaò¯IH<GÆY@ NAD+(6.(H1[:I"AM¶I<G IDH* ULXZ NAD+ÂñMÛi°tMÀúH1[ NAPRT*6
jï;\[:I^µá<B!RB:M¶m^lh<G NAD+ÂñÀú NAMPT M<2ûÈ6 IDH*
UÜvï¸L¬TGchH1[:I^Ó<B%Tateishi K et al. Cancer Cell. 2015&!<5<K6Yò!
PMh^¾o<BÇLN|ùð"cºð^¼LÁTBÒpXMn6&I<GÊEG2[!NAD+(^¥/>[UMI<G÷âM-Z NAD+Âñ°t6àiH1[6"TMiI<G NAD+æI°t6©
9Y\[!$L2K NAD+æI°tI<G DNA ÞOLJiK poly ADPribose polymerase%PARP&M
ðKJ6©9Y\[!÷âM TMZ N O-%*)'&MSKY?d`mzÊ}LUuiw

M N,"N.%0)'&^N>[6:DYN PARP °tMðLXZ,DLÞO;\["ÆY=ðLN¡g<K2:I6G]<G2[!éóÙYN:MÞO¤½L*_<"TMZ 7gLXZ PARP ~þðL NAD(MÍn%%´¨ Cê°¿Ä

IDH' ép0E7 DNA ²æéwC~î?¡ÂÑªB<1»¬ùëCá12+µã0Ã6N?xÆQø=" IDH' ép½ÿ|°BÌ5= TMZ ? NAMPT È¥CèõBKN°þy0É4ON/ØQ-3?QíCïÔB29!
' % * +"! in vitro )(#! IDH" ]>)I1*WS79=70B_
DNA ²æBD PARP Q}59 base excision repair%BER&J single strand break repair CGA
L8 double strand break BÌ7N homologous recombination"TMZ BKNf^jåzC MMR A@0+N!£³B IDH' ép½ÿ|°¤ìBÌ5 TMZ ×óQ,¤ìÝÁy"NAD+µã"
PARP ÁA@QØ59!F9 NAD+éÙ0 PARP nËÁ/QîL/B7N9HB PARP È¥Qõ
,9ýw0Ã6N/Ø59!
$!TMZ . NAMPT VDP0\`/34O^ZUMA0JY
ÞtÁ IDH' ép½ÿ|°¤ì" IDH' ðÃ½ÿ|°¤ìQõ,= TMZ ? NAMPTÈ¥èõBKN°þyQ CellTiterGlo S_\TB=Ø59!F9èõBKN¤ìÞ NAD+ÐCéÙQ NAD$NAD*S_\TV_bQõ,=Ø59!
%!C@U IDH" ]>O^F5`(+ETRKèõy0 IDH' épB<1IC/îL/B7NoB"¼Ä®L0±ø59`bhXTWilòÛ
v IDH' épÀá½ÿ|°¤ì%MGG18 IDH1 R132H&Qõ,=¤ìÝÁy"NAD+éÙQØ59!F9 NAPRT' öÀgajQ§Â5"ÚôC°þy0+N/Ø59!
&!O^ZUMA. MMR HN2 MGMT ?XQ[L.0GaU/,(-0JY
èõy0 TMZ ÍÁBü7N MMR qÕ©épJ MGMT dkg#]#ûrCf^jw¹ÎBu
4ON/Ø7N9H MGMTf^jw"Óf^jw¤ìQõ,= MSH6 öÀgajQ§Â5°þ

yQØ59!
'!O^ZU<6:8;0JY¤ìÝÁ0Seb#Y[nËÁ/U#bcRZ#nËÁ/Ø59!FACS"western blotting ëB=~Å7N??IBSeb#Y["U#bcRZ#È¥B=¤ìÝÁyBÌ7Ný0ÜLON/Ø
59!
#! in vivo '%TMZ ? NAMPT È¥BKNèõùë0 IDH' ép°þÙçgajBÌ7N°þyQá7N/"BD NAMPT È¥úv>IÚôCy0ÜLON/Ø59!
' % & $"! in vitro '%#! IDH" ]>)I1*WS79=70B_

IDH' ép½ÿ|°¤ìBÌ5 TMZ Q×ó59?3P"àÖnËÁB¤ìÝÁQòÛ7N3?0
âî59!9:5¤ìÉºöÀyD)ßïmBÃ6"3OD TMZ Cñ÷§õ%MMR nËÁC futile
mismatch repair &BKNIC?.LO9!sê TMZ ×óÒKM¿«

mÞB¤ìÞ PARP ÁC·´??IBÏ¯¨ç>+N poly ADPribose%PAR&0{¸B¨Ã4O9%¾'&!BD PARP
Á?üÙ5 NAD+µã0Ã6N3?0âî59%¾(&!3OLC¶D PARP È¥>+N olaparib
B=ý0Ã693?/L PARP ÁnËÁ>+N3?0âî59!3C3?D TMZ ×óÊBÃ
6N DNA f^jåzBÌ7N²æ0Ç¦ÔA¬ùäÔ?AM-N3?Q­¢7Ny>+;9!

2 R r  C . J G

E! TMZ KS=+ PAR O<+Q3

13

E" TMZ KS%B9=*1'. NAD+J+QL"!TMZ & NAMPT ;07(>A')*6@=:5.(3<qBV| IDH& Uye¢Zt^m]?.N MGG&&-"MGG&*'"BT&)'" IDH& Uktm]?.N HT&%,%Q/> TMZ @ NAMPT [nQ8<@6P"/:OCmB0/>I
TMZ C

S|B NAMPT [n@ChY2~9N6@28<#z($!6CgxD IDH&

~dye¢Zt^m]?.N MGG&,"'(",*"-&"&+&?DHLOA1=<6@1L"vA4@
I IDH& UmB0/>D TMZ @ NAMPT [nChY2a?3N6@2sl7O<!F<
NAD+D NAMPT [n"TMZ @\8"X?Dc

B{7ON6@2;>8<#z)$!

E# N0F IDH! Q/D;V5C8@R7*H(. NAMPT G6A) TMZ PT*-.?CU>4

E$ N0F IDH! Q/D;V5C8@R7*H(. NAMPT G6A)
TMZ IM:,PT2*&'. NAD+J+QL#!/-: IDH ?,6@2+A$%1984
MGG&,IDHR&('bE UACC'*+ IDH& m]Qo}8hYQfw8<@6P"c{ IDH& Um]B0/> NAMPT [nC_u|2jFN6@"iBD TMZ @ChY2TBHLO
N6@2L1BA=<#z*$!iB UACC'*+m]B8 shRNA Q/> NAPRT&Q{8<@6Pc{ IDH& UmBW5Nh@¡p8<gx2HLO<6@1L"m|hYD IDH& UBKN NAPRT&gC{2`8>/N6@2L1BA=<!6OBKM NAMPT [n@TMZ CD IDH& Uye¢ZtB0/>BAr?.N6@25LO<!

IDH( Æg2|E8 DNA ÄyÆmBpÌ?¢°Aw<3zÑÉBq¿14Q) L!HR IDH& \@M];8=2P_
B6<:! IDH& \@HR;8=#IDHR&('H$07?9>"=#GFP$
1-.4 NAMPT TFNUXG3 TMZ 02[^D1-.4KO`JE2IV"!8?=:61' MMR 37* MGMT 0;9>5')2@:(%$&)4<
MGMT bYdm$MGG(*)%ÂbYdm$HT(','%ÊOÏ.=:L MMR vÒh´>-L MSH

6 OÐ 6"TMZ «¡ÊcZdO¢6:!4MJBÊOÏ.= TMZ ? NAMPT ¥rBÅÏÑ
ÉO¶6:?4N".9MH¦n2Ç:ML4?2ÀÌ6:!4B4?C TMZ «¡|DÃkÕoA0.=H4BÅÏÑÉBn2x¬5MLHB>-;:!
#!8?=:/+-,.)4<Ê¹¡bT\Xa?6=

S#[]PV#AvÒ8L®¾¿

2Ó6=.:!F:Q_[#UWÂf©¡>-L4?HÀÌ6:!5JAS#[]PV#¥rOÏ.:?4NÊ¹¡nAÐ

2£7:

4?1JÊ¹¡C NAD+tAI;=£7: ATP £²lA{j8LS#[]PV#AILHB?
/JM:!
"! in vivo $#TMZ ?ÅÏ8L4?>"²½µ NAMPT ¥rÑ2½µl>BÑn?·ÎBÔn2¸JML1 IDH( Æg"Í£ÊuOÏ.=¶6:! IDH( ÆgÔAª6A NAD+¯O¨³6:?4N"½µ NAMPT ¥r?Ás6 TMZ ?*'&½µB NAMPT ¥r>·e^dB NAD+²l2Ô¤»>£7=.L4?2ÀÌ6:!4B½µOÏ.=`RW IDH( ÔAª6=Ôn2£7L1¶6:?4N"NAMPT ¥r"TMZ ­ºÑ?Ás6=ÅÏÑÉ>C±@Ôn2£7L4?2ÀÌ6:$+%!iÈ IDH( Í£Ô>CÔnC¼GJM@1;:!

Q* YAS IDH& \@O`#HT&%+%$5^,/WZ;8=1C.4KO`JE2IV%&

4MF>B}|DË}AIK"NAMPT ¥rC IDH( ÆgÕAª8L~.Ê§Ð

4 V  Å H 0 O L

15

wcU¾;S7D4»Q3GF@?%Tateishi K et al. Cancer Res. 2017&!7H7DI IDH( µ\U°D9?ÄHu´a^ÅD9B`Âb«FÅ·C0S7DU;SNHC0S!_¶C NAMPTfH¦GA1BIÄ3Q

8TB2R"7H¦U|±9F5TJÈ`ÂI~¨FlG0@?!ºsiGPRqÊdG;S°agÅ·C0S TMZ D NAMPT fH³ÂÅ·GP
R" IDH( µ\ÉG9BPRkÇFxÉwc4:SHLFQ<"NAMPT fUtÆ9BN¤ÁHkÇF¸¦4:S7D4®»9?!7H7DIPRkÇC3AZH{1Å4n1Ä¡eb«GFSDh8=SrcC0S!_¶Ch

F½²ÅI~¨C0S7D4¿8TS?M"}vIyG¦Ut;S7DU¼°D;S¯Ã40@?!o

GI IDH( µ\qÊdH¹E4m­U;S7D3Q"NAMPT fHmKH£ÀU¼;¯Ã40@?!>7C MIT DHj¤siUz1m£ÀÂH microparticle Ue­9"YWX¬ÉGm£À9?»FxÉwc4©MQT?%Shankar GM et al. PNAS. 2018&!7TGPR}vª[§G IDH( µ\qÊG;SÈ`ÂGAF6S7DUFSsi¼°Gp6B1S!
!

%

IDH( µ\qÊG9 TMZ D NAMPT fH³ÂÅ·I]¢\G¥\ FÅ·C0S!
% $ " #(&Shankar GM, Kirtane AR, Tateishi K et al : Genotypetargeted local therapy of glioma. Proc Natl
Acad Sci U S A 115%36&$.**./+")'(-#)&Tateishi K, Higuchi F, Miller JJ et al : Alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1 mutant cancers and potentiates NAD+ depletioninduced cytotoxicity. Cancer
Res 77%15&$+(')(,")'(-#*&Tateishi K, Wakimoto H, Cahill DP : IDH1 mutation and WHO 2016 diagnostic criteria for adult
diffuse gliomas : Advances in Surgical Strategy.  Neurosurgery 1 ; 64
%CN_suppl_1&$(*+.")'(-#

16

ÖH28Vd[m`[~eco|I+ã

4/21#!"%)&+'&.*(,-$3605
ó°µ)*&% IL6 eco|I^u]bi$E;C JAKSTAT3 ¦Q4GAD.V4"½£"øÈJÝ@G^u]bi$E;C
SrcYAP ¦QY-ª;"ùI¼áHÍJD.V9EY9º;@!»I©¢DJ"Ö4ZEÖ¼áH28V×"
SrcYAP ¦QE JAKSTAT3 ¦QIà´EEYBT3H<VÃYDþE;@!O=ù_|ar[nH2/C4
ZKß"Á APC I§ëHSU SrcYAP ¦QE JAKSTAT3 ¦Q4à:WVÃY-ª;@!:TH SrcYAP ¦QE JAKSTAT3 ¦QYæ¿D%ÄHKß<VÃDô¿#HH.NCñù4Z"Té4Z"Ü&4Z¾<IèÛYSU¯þHKßD5VÃ4BT3EGA@!Src æ¿E JAK æ¿J<DH 54ÅNFE;CìIÇHÕ*:W@U"
Å«4·XW@U;C/V!?I@P"»I©¢¨JtmMIPÔIQçH·09E4+Eð:WV!

# ! $ "
ñù4Z"Té4ZGFIÖ4ZHSVÂ=LJåE;C¸6"çD.WK(þÅNRþäÑ4+D.V4"Þ·4ZR4ZI¼-IÙ¹JÉHN;4·XW"?I¯J®ûþD.V!
CN;E;CCj]kbv[~mæ¿&³ PD1%PDL1 ³ïN;'4÷D:WC/V4"y{r$wGFDJO±G¨4ÐC/V:"í6Iñù4ZDJ.OU¯4G/Ã49º:WC/V!?

à×4í6I4ZI-áRÞÿ&!'HH;C/VÃ4S6õTWC2U"?IöDQ×àd[m`[~ IL6 4ñ5GEY@;C/VÃ4õTWC/V+','!
IL6 eco|I^u]bi$E;C JAKSTAT3 ¦Q4GAD.V4"½£"øÈJ SrcYAP ¦Q
Y-ª;"ùI¼áHÍJD.VÃY9º;@-'!øÈJ"×àùÇRñù4ZDà;C/V IL
6gp130 eco|YùØ0¾<'þHà:>V@P"gp130 I²Úþà¤8&×àËSIÈ3T-ª:W@8'YI/C"ùØ0¾<'þG gp130 m{~gf]pkbw\g&Villingp
130 Tg w\g'YÀâ;@!Villingp130 Tg w\gI3­¤E;CJ"ù4ú6î6GU"èÛ;C/
V@ÏGùØ0¾<IèE7/¾<&sq$m¾<",¾<'I¬ÓY*P"ùzl|Dùü³à
YÆ;@!?I3­¤Y5

9<y`phxE;C"gp130 IMD JAKSTAT3 eco|H1"Src

YAPNotch E/0eco|4à;C/VÃY-ª;@!ùü³àH2/CQ"gp130 IMDJAKSTAT3 eco|H1"SrcYAPNotch eco|4ÍJG$5Y@;C/VÃYBT3H;"
SrcYAP eco|4×àùÇI

ÊD.Vb}$~4ÈIùDQà;C/VÃY*;@!

øÈ4-ª;@ IL6gp130SrcYAP ¦QJ"(×)E(¼á)YBG7Ýeco|"ò¦QD.
VE¶1TWV!
¼áYêÞ<Veco|Ií6J4ZH2/CQà;C/VÃ4õTWC2U"9Ieco|44
ZH2/CQà;C/WK"4ZIÝ;/ÅN2þHGV+à4.V!>©¢DJ"Ö4ZRÖ¼áH28V×2SL SrcYAP ¦QIEYBT3H;"ÝI4ZÅN2þ#ÅN;Y-ª;C"Ý;/ÌþÅNYýÒ<VÃYDþE;C©¢Y·A@!
*¥R¡Îñ5 1á6#C7 Y ¨ ï H 3 Q M

#

17

$

äCI"±}7Y'ÊÍ7Y"òÃ7Y"·×7YFE(P±}H¾G58U|²5RJÌ«7Ü<@ SrcYAP ñ'|²GRT¼};VU¸ñ(HèXåS6G<"¸H¨ïÞÐ$¨ïâXÏ°=U¦XçÐD<""*#±}7YG58U

SrcYAP ñH¼}r^kc

q$èHå"+#±}¾G58U SrcYAP ñHèHå"X¢½<@!áâD<BI¬G

ã'Í]u_lZi"7Y

ãFE(Pp[bXí4B©XA@!

#!815&+(%'* SrcYAP 6=)4910,.-/"<3)2;
p[bÍ]u_lZiPmh·×7Y

ã'TE1"TE5"TE8"TE11("mhòÃ7Yã'Panc1 D MiaPaCa2(Xí4B"SrcYAP ñP JAKSTAT3 ñ7¼}<B4U6X[\bexnwfhâGBÔ<@!L@·×7YãPòÃ7Y

¡H~X MTT assay CÔ<@!ÈÐGI"³ÄÎ¥é SF'j^tZ(X£í<"ãHÂ´GÉ=U Src Á¡D JAK ÁãX2/ well ov%hKÛ­<"¾ãºãHÂ´ÅÒXÝÔ<@!Src Á¡D<B AZD0530'Selleck(

D Dasatinib'LC laboratories("JAK Á¡D<B AZD1480'Selleck(X£í<@!
$!8157:(%'* SrcYAP 6=)<3)2;
duvZxêÜ¼ò|sguXí4B"SrcYAP ñH¼}'duvZxÓë)"*","/"*+"+-"
0+"/1§HeZq`%b(XÔ<@!1¯ðH C.0BL&/p[b'rb(GduvZx'Sigma(.)ug&
kg X*§:DG0ßÙËªCÓë<"¼ò|XêÖ<@!®<@axouXí4"[\bexnwfhâDæ{Àµ}¿¶âGB"SrcYAP ñP JAKSTAT3 ñH¼}XÔ<@!
"!

#!815&+(%'* SrcYAP 6=)4910,.-/"<3)2;
Í]u_lZiG54B"SrcYAP ñD JAKSTAT3 ñHÕ§¼}77Yî»zÑ¤ APC'adenomatous polyposis coli(HÇGRT9U¦7W6A@-(!;SGmh·×7YYãPòÃ7

ãG54B"Src D STAT3 H¼}D YAP HÜXÚN@'¹*"¹+"¹,(!Panc1 G5

8U YAP HÜI Src GyÆÐC3A@'¹,(!L@òÃ7YãC Src D STAT3 H¼}X Src

Á¡'AZD).,)5RJ Dasatinib(D JAK Á¡'AZD*-1)(C>V?Vî»=UDãÂ´7î»;V@'¹-(!;SG>Hî»~I Src Á¡D JAK Á¡HàíGRTÂ<@'¹-(
!L@·
×7Y

ãG58UÁ¡©G54BOÕìH~7ØSV@'¹.(!

1" 03$*/5-'#%) STAT3!Src (,2+& YAP (4.

18

4/21#!"%)&+'&.*(,-$3605

6" ?;&+3=0(%'* STAT3!Src )/8,

6# ?;&+3=0(%'* YAP )<1

6$ ?;&+3=0(%'*9.4):5>72-

, > W j 4 ( 8 619?" >G&.;I8*%'-B6<+C=L@:5"!.(+-/%#$' SrcYAP ,2&1*&)0
DJK?Mbi39;hc-</kO4kaBMIJ3*)0"biV`T+:4 STAT3 7 Src 4S]P2VT+:4 YAP 4eUYX=@ACEMHLFGf1Qd./$\&%!5/DJK?MbiV
4 YAP 4eUYX#S]P=gN_ZPR^[f1Qd./$\'%!

?# 012/3EK*,-MD(+ STAT3!Src +7A4) YAP +H9JF?$ 012/3EK*,-MD(+ YAP +H9JF

ÂK8<Yg^mc^whfouLêÏ

20

'

(

IL6 hfouLar`ek'H@F JAKSTAT3 ':ùôG4Y:"®"Ü»MÉDJar`ek'H@F SrcYAP '\ë¡@"ÝL­ÎK¿þG4Y>H\ðª@D-)!@9@">ZWLhf
ouâØ'L:]GL÷UÖÔL­ÎGL÷Mä?ZF5J9ED!
C>G«LGM"Â:]HÂ­ÎK8<Y~Ã"SrcYAP 'H JAKSTAT3 'LÍ§H÷\õW9KAYµ\öáH@\©ED!QBÝbudp^nK85F:]ÿÌz

â³ APC LÕKVX SrcYAP 'H JAKSTAT3 ':Í?ZYµ\ë¡@D!?WKqm)Ô:]¯òUÈç:]¯òK85FT"'MÍ@F5D!SrcYAP 'H JAKSTAT3
'Mè!@Dhfou'G4X"ßÅÆ×GMPH]IÍ?ZF8WB":]UÑÇ­Î¶K
;Í:úæ?ZYµ:>ZQGL

9Wï9EF5Y-).)!CLDS":]K8<YV5·#íá

H¨7"Src Ò±H JAK Ò±Lå¶ãû:ÙèãûVXT:]·#Kù¤GMJ59HLÐ\!
FD!º°")Ô:]¯òUÈç:]¯òLº¢G Src Ò±H JAK Ò±Lå¶ãûMÙèãû
KìOFVX¤áK½(\ÿÌAY>H\é@D!
QDÍ)~$)­ÎLs_itluG4Yjuv^wúë)~tluK85FT"juv^wãûKVY SrcYAP 'U JAKSTAT3 'LÍ\éS">ZWLhfouâØ':ÝL­ÎLRJWB)ÔL­ÎKû@F5YêÍ:¸¬?ZD!

yÄLVX"SrcYAP 'Mü&J¼%LÂ:]U­ÎK¿þJ÷\D@F8X"Â:]LÉ@5·#íáHJY

êÍ:¸¬?ZD!
! $ # "

Src Ò±H JAK Ò±MAGK{î:·#øH@FÖL¹KÁé?ZDX"·¢:©[ZDX@F5Y!CLDS"«Lº¢MqmNL$ÀýTÓK©6>H:êH¨7WZY!SrcYAP'H JAKSTAT3 'M#ñà¦ÍKTû@F5Y>H:ÛWZF8X"ÞÅL#ñK
7F"Src Ò±H JAK Ò±\å¶KãûAY·#ñ::]L·#KVXù¤Jó\´}@F?ED£|²ÚñË:]¾á·#

êÍ:4Y!

²ÚL»LüK¥;8&Ê@Ä=Q

A!
% * ) &+)Taniguchi K, Karin M : IL6 and related cytokines as the critical lynchpins between inflammation%/.1.",*+.#and cancer. Semin Immunol ; 2 (6 1),)Taniguchi K, Karin M : NFxB, inflammation, immunity and cancer : coming of age. Nat Rev Immunol ; 18(5)%-*3,.",*+2#-)Taniguchi K, Wu LW, Grivennikov SI, et al : A gp130 SrcYAP module links inflammation to epithelial regeneration. Nature 5 ; 519(7541)%/10,",*+/#.)Taniguchi K, Moroishi T, de Jong PR, et al : YAPIL6ST autoregulatory loop activated on APC
loss controls colonic tumorigenesis. Proc Natl Acad Sci U S A 14 ; 114(7)%+0.-2",*+1#

7 a Ì d N 1 Y U

21

CSMP?HNQ DNA -O#&60234./51")>8(<'$FEKJ!FE=9T;(G%,D:IBR)@L7*)A+<#F)(% ïØ7ç<^CjMþ=HÌdMæ`ª+?]Ã"ÅNL2ïØ7;6$J23É06[ïØ;ëIf
7L<^]!Q¯ IO"ïØ`ç=CjN¬([b DNA'cellfree DNA, cfDNA(N KRAS 1ÆK`nilz PCR `^2Hú+="ùßIOïØ;Jå%<^CÝgI1EHW"G·ôáÂOå`ëgXÒiu&f&¹&g
LK"@Ù/NüÄXD±ëN/7_^]ÝgM KRAS K`ëg7ý2¦¶71];J`°Õ=C!¬( cfDNAN KRAS Kú+Oùå%IO®ÕD;L@Ù/Nå%TCOD±ëN/Õ³N\úMZ^L;ë7Í¾<^C7"ÚêgN®5I1\"¼´OÀ=#\´LKNeÛbdofvJNhMF2H®5`4]S9"ÝgNÓî5ZQí`¨û=H29\+I1]!

# ! $ "jÑ}2Y"/>Z\"ÔaNjm&iIfM4HïØ;ëIf7äCM*<^C!ïØ;ëIfJOÔa TNM

ÆMG2CBIfJOL\"ÐMÐ_6UJNðãN,2`A?];JI"ÅNL2ïØ7;6$J23É0IIf<^]WNI1\"ÐMïØ`ç=CÝgMþ=H~`Z?]WNI1]!=6=L7["ïØ;#ïØ¢#ïØD;JA^B^If<^CBKMþ
=HKNZ3LÌdóc7Á.LN6OSDV[6IL2!
ïØD;#À=jMþ?]ä{iw|I1] Gemcitabine+nabpaclitaxel dN5ZQ FOLFIRINIOX dNNZµë`ÇË?]«7»8IW'î<^+(,("7M¥:O;^[N{iw|`ïØ`ç=CjMþ=HÖöÌdJ=H¸3Ìdóc7)W<^H2]!³Ä"4¤Î`VCHêN»8Nqc
tyx&vk|l&IANZ^ë`®Þ?]]%LeÛÊ²7©#è¸(I1]7"ïØ;ëIfM
>CÖöÌdN.?"Ìd{iw|"ÌdN'dN6LÏõdN6(LKN0M52HSD
+N×OL9"ÈñRML]Ìd7È<^H2]N7³âI1]!
Q¯

NW-O"4M5:]ïØçjMþ?]Ó-ÌdMrceu&f&¯`Eé<@"7Mùå%IO®Õ½9L@Ù/å%M5:]¬rceu&f&NZ^ë`V[6M?];JI1]!jådM52HOÁW¹C2MU[^]1ÆàI1] KRAS Kb{z`hpvu&f&J=H^2C®57ý27-(.("ÐMå%#\´\úu&f&J=HNZ^ëMF2H®5=CWNI1\"
ïØçjM5:]Ó-ÌdRNZ^ëMF2HOV[6IL2!rceu&f&N«MG8"@Ù/å%"5ZQ@Ù/NüÄ7£9_^]ÝgMþ=HÖöÌdò¸<@]J23Ó-ÌdN÷J#ìT7;ML^P";^TI9ÌJ<^H8CjN\´¶ßRNs{cgjz&JL\
3];J7ÿ<^]!
'&,*+/:++­6[,*+0:.­TINM3P!Bøº'¡$j(Iì¿TCOÌd`¸E)3P!!§¯  ÜIX

ubkoq^`re&QWZQ¿ò¸FR§0

22

HQ43K\èÊNDH!43KâKQ<;L¸FàQãÍòQQßNÑêC[L;Z!
¦²"*£·E\A;HQºRÑê$¸FQEZq^`t&a&\î®EZ¥+NDLø7éé¡¥HCzWYÇÿ\¾A"ù¹MÜÅ\ÓDLÚ®$¸F>µC[HQ\èÊQà©?Q£·E\¯¼DL;Z(Çÿ&­1/070137)!8¥RèÊNPIH43KâKQè
DLU§0QÝ;Nü{¼ý\«IH!
#$

9È£WYâ£\¯¼¨"òæV=QÏ/DD"£OÖ/\/íD",7/-M÷¢3çDH!´
AQ±DLS"£O\÷¨Q03"///g"3-M0//ÏD"ËØ1#/mL =X circulating cell free DNA
extraction kit(QIAGEN)\A;L cfDNA RìÀ\«IH!cfDNA Sï!öM=J¬öQê2C[

L ; Z B N = X"! ö å ð S LINE1 $ L \ ( ò N D H PCR 6 Q L « ;"( Á · E M : Z humangenomic DNA(G2/30"Progema)\A;L¤GÞ\³ÛDH!
ýX[H DNA \lxrw&nQ KRAS tvjgcu&pxdbkn(Biorad)\A;L KRAS ~õ¶R codon01'02Rôþá1|\?EZ]wv+ö\mfiv PCR(QX1//"Biorad)\A;LðG
DH!Quantasoft0.6.3(Biorad)\A;LBÕRñÔ\a_xnD"s]hx/-QK@4×¨"=Ù"1|R]wv+ö\F[G[åðDH!
èÊÉKWYýX[H»#"äÑê"½Pt&a&"Î®.ª¤®PORIÆÌ5\ÑFN=XìÀD" KRAS 1|]wv+öNRMÕQJ?'¤úDH!IÆ*SQ¼Yy;>6%
QK?/JD"ÜÅ"Õ/JU>QK?"ÜÅ"(R)"ÜÅ(BR)"ÜÅ,"(UR)Q/JDH!CXQ>QK?"BR QS<:(BRPV)"û:TRÐÂ(BRA)"UR QSÃÒ«(URLA)"ó}:Y(URM)QF[G[°/JDH!
"
43KR»#!

SëÕ21K"ÄÕ11KM"¸FàRä¤®QK@Q<AZIÆ*SF[G[ Stage

9'II'III'IV%7'17'0/'7KM:IH!ü@Q"ÜÅ"Õ/JQJ;LS R >18K"BR >0/K"UR>7KM:IH()0)!
&! "$%#

Variables

n

!#"

Sex

Male
Female21 (48#2)
6)
11 (3/#

Location

Head
Body and tail20 (46#3)
5)
12 (31#cStage(JPS 7th)

I
II
III
IV

7 (03#
7)8)
17 (40#4)
0/ (07#7)
7 (03#

Resectability(JPS 7th)R
BRPV
BRA
URLA
URM

18 (42#6)5)
2 ( 4#/)
6 (02#/)
6 (02#
7)
7 (03#

Treatment04 (16#7)
8)
10 (27#4)
06 (20#8)
0 ( 0#

Upfront surgery
Chemotherapy.surgery
Chemotherapy
Chemoradiotherapy.surgery

7 [  ­ I 3 S P

°TVUX@ cfDNA I®Z_a$^¦"m23¥¯¦H¡nt=WF"Stage2

°H69Ws±*mL 3@VI cfDNA ®JlE.#0)ng E3V"StageIV I/#
1)ng F¡LG4r
vH3B@!O@"m¥¯HC4DQªIrvE3B@&*'!

4# *+")=!63/:5<C='18?A02'7B~H"b^`d PCR E;X@ KRAS h}§f\ed£HC4D¡nt<@!R ³pJ+1°-°E§f\ed7t;X"«¬J*-(E3B@!i¨"UR ³pJ*.°1°E§f\ed7
t;X"«¬J/)(F3B@!{¥¯<Dzt<@F:Y"URLA °E.0("URM °E
J/,(E3V"qx°Fkog°EMNI«¬E3B@&+'!UR ³pI KRAS §f\ed«1°I5A"|I§f\ed£JlE)#,(E3B@!i¨"R ³pI KRAS §f\ed«-°I§f\ed£J>X?X+#
*("*#
)(")#
.(")#
-(E3V"RRKUC87uUX@&,'!R ³pH69W KRAS §f«°I{Z¢+H=!-°+°J¤w{©7«
&CY1'E3V"*°JsjI²c$]$E3W DUPAN2 7*/")))IU%mL FfyZ<D4@&¢+'!

4$ 63/:5<C&18 cfDNA 8' KRAS >.@5;9

4% 63/:5<C&18 cfDNA 8' KRAS >.(-,;9pdhjl`bmf&OWZù¨~Ò£òPãx

24

3! *1 cfDNA % KRAS 4'5/&,#$0-(27)"6%.+

No.

Age

CEA CA199 DUPAN2

Location cT

Size
(mm)

cN cM

(ng//mL)(IU//mL)(IU//mL)* --'4

0#
)

**,#
.

*/)))

Ph

,

,*

)

)

+ //'3

+#
/

+1#
/

-*

Pb

*7 *.

)

,* /.'3

,#
.

+.-#
.

*20

Pb

,

+.

/* 1+'3

,#
/

.)#
1

,0

Ph

*6

0

CY

Stage cfDNA Qty KRAS MAF(JPS7th)(ng//2mL plasma)(%)

Class II

IIA

*)#
-0

*#
)

)

Class V

IA

++#
+2

)#
.

)

)

Class V

IIA

.#
)-

+#
*

)

)

Class II

IA

0#
)0

)#
-

Ph, pancreatic head ; Pb, pancreatic body ; CY peritoneal lavage cytology ; MAF, mutant allele frequency&'

Á«]ºEHùOÉFZÝ¬ÔtP¶ËQ¨~Ò£òPÓwMæ¹ÑOÐFZHT"9¾Ö>TX[Z!çPzLQ"Î cfDNA P KRAS äsï¼ðQ¸õ=JÁ«àÛõLï¼ð
>@"ó®ßVÁ«yÛ¼âôMP÷>¤D[H!C[XPz=X"åMØìOÎ cfDNAP KRAS äsQÃ·¼PÔt]¶ËFZl`bn&c&MNY:ZyÛ¼>¤D[H>"væLQ5ù]¾ÖO¶ËFZCMQÚL8IH!E=EN>X"5ùL8IKUÎ cfDNA P KRAS
äsï¼õ>Ç·OÝ¬ÔtPÇ

E"G[XP¯õQ CY1 õV§øn&c&s³Íõ]¤EK<Y"áÙSHQÃ
>\[Z¯õL8IH!áèÔt>½ñFZÂÌ|M{¦D[K9Z CY1 ©MÃ·¼P¼ÔtPl`bn&c&MNY:Z cfDNA ÎP KRAS äsO÷¼>¤D[HCMQé´@"QWYÈ»õLP×>ÞîL8Z!
! $ # "
Á«yÛùO<AZÎ cfDNA P KRAS äsï¼õQÔt$ÜPk`pgeMEKÄãxL
?ZyÛ¼>¤D[H!E=EN>X"­»õP×L8Y"cfDNA ÎP KRAS uÕ¢äsÅÑPr
]êX=OFZHTOQ"É°¯õPÜ$ëOFZó®_aico]í9H×>ÞîM;"U¯õP¨À<WR{¿]ÆEK9@ëÑL8Z!
O"CP²]<¥YEK"ª½]Ï9H>^¨~Ò£ò¡ÊP}qO@ö]µE
±BSF!
(

%

*(Ueno H, Ikeda M, Ueno M, et al : Phase I/II study of nabpaclitaxel plus gemcitabine for chemotherapynaïve Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol
77%.2./),"+)*/#+(Okusaka T, Ikeda M, Fukutomi A, et al : Phase II study of FOLFIRINOX for chemotherapynaïve
Japanese patients with metastatic pancreatic cancer. Cancer Sci 105%*,+*/"+)*-#,(Takai E, Totoki Y, Nakamura H, et al : Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep 5%*1-+."+)*.#-(Ako S, Nouso K, Kinugasa H, et al : Utility of serum DNA as a marker for KRAS mutations inpancreatic cancer tissue. Pancreatology 17%+1.2)"+)*0#

6 V ² - G 2 N K

25:D?F7H=8(N#'>4*2/M+3.-51)04,6(KO"$!
BI;%G#'C<LAE@P&9JÓã,#(&% ê²ÉC2RÄç0öÃïFØ<R²-üD;B"~û¶Î-ü6í|×5AßÅ¼E²-D;B¹½D
÷I+;B3R!:PER²-ÊÌGÃFHû¶Îá¡ÉGÏ6GÛC2R!û¶Îá¡ÉG·EzD;

B"û¶ÎFOQ'æ:S?­©ýU±AÉ®Ð%y} ROS&FØ<R6V©ýGÞ/¬)6¢4PSB3R!§
 #H"¡tZph&D;B.ÀâF¯):SB3R`sfcunWmtbvG"ROS GÞ/UÑ<R¬)FÝ%;"`sfcunWmtbvDû¶ÎÁ¶Gõ)FORÄç0öÃï©ýG¡º1FA3Bä;?D9T¡º1GÓUëM?!ÿFOQ`sfcunWmtbv6"6V©ýUðâD;?û¶ÎÁ¶GÓªD;Bí<RíÉ6³¨:S?!«"pZcU)3?ÂµEPIFÓGr]kdqG#U£@B3R!

# ! $ "
ê²ÉC2RÄç0öÃïFØ<R²-üD;B"~û¶Î-ü6í|×5AßÅ¼E²-D;B¹½D÷I+;B3R*&!Í¿íÄçFØ<R~û¶Î-üH.ìË×*,0'%ÚwÒ°
JCOG11)/&D"Ö<J7ÜCHE3!:PER²-ÊÌGÃFHû¶Îá¡ÉGÏ6GÛC

2QÆû¶ÎÓªGîD>GÓU(Õ<RlY\p$]$Gåà6Íþ:SB3R!
û¶Îá¡ÉG·EzD;B"û¶ÎFOQ'æ:S?­©ýU±A ROS 66V©ýFOQÞ/:SR¾6¢4PSB3R+&,&!6V©ýCH CD44 GltXvj%CD44v&6¤î;B3R!
CD44v H38AGltXvj6ú¥:SB3R-&%È*&!>GltXvjGÞC"[^ev*+*-UL
CD44v Hº1©ý!ñ$Gachvjsvco$g$%y} xCT&Uxà~:=R9DC©ýachvG¸Q¦KUÓ:="¡®~ô´C2R_ugh\vGËÊUÔÇ<R9DFOQ ROS UÞ/;"©
ýé ROS Uß8ù@B3R6"èF9G ROS Þ/aciqFOQ6V©ýH ROS FOR­©ý
F¤3á¡ÉU³<D¢4PSB3R.&%È+&!

/$ ,* CD44 +-&.*"CD44v# %!'().

(»Ùò{øóò{ 26

SkYVmcLblUoJÕä8:"°Ì>¾9H±Ù¤¸¢ë?|Ñ

6! "%258$ ROS 1734#'-*)/,&+.(0Î"lNgZâ=8;ä7IHßuÄ´âSkYVmcLblUo3"ROS ?Âîæ²>EG¥ðzJ£96=3Ø7I:)','!SkYVmcLblUo@ xCT ?ÏJæ²9H6=< ROS?ÂîTV\hJº}9H)','!­?SkYVmcLblUo?¥ðz3Ãá7I"^k[RlfUTj_oRâ=8;ì«wä9B4"ÝÜ>10;

7I:r>¾9HSkYVmcLblUoÁ

Êã?Àt»¡<@"CD44v å³Û?ª3~Í7I-'"Ó©ÛÐ>¾9HTVdkZo"ei]nPW^=?SkYVmcLblUoÕäëÚ?Àt»¡<@Þ¼pµ½é?vÅJÍD:.'!q­2F"Ù¤¸¬¤=3KÛJÔÈ=8:SkYVmcLblUoJÕä9H6=>EH¥ðz?¼3¿7IH!
Ý@°Ì>15HSkYVmcLblUoJÕä8:±Ù¤¸¢ë?|ÑJáÈ=9H!
#"!$%(#a]°ÌïÖ­Ò3KÛ?"OPXo1214J

C CD44v&qx CD44v13'Ñ=SkYVm

cLblUo%Ù¤¸¬¤>¾9H¦³=?í('CD44v13 Ñ1EAÆÑa]°ÌïÖ­Ò3KÛ?ËÇ&FACS"RTqPCR')'SkYVmcLblUoÁÊã>EH CD44v13 Ñ1EAÆÑÛ?¥ðz&MTT assay, FACS'*'SkYVmcLblUo%Ù¤¸¬¤Õä>EH CD44v13 Ñ1EAÆÑÛ?¥ðz&colony assay')#CRISPR Cas9 TV\h>EH CD44v1214 `[QMN]&qx CD44vKO'a]°ÌïÖ­Ò3K
Û?§ê="Ù¤¸¬¤>¾9H¦³×y('CD44vKO Û&OPXo(*?·è'?§ê&CRISPR Cas/TV\h')'CD44vKO Û?¼®Ï&MTT assay, colony assay'*'CD44vKO Û?Ù¤¸¬¤>EH¥ðz&colony assay'*#RNA T$QOoVJä0: CD44vKO Û?àçÈsÉÑ{¶
Pathway {¶&RNA T$QOoV'+#Ù¤¸¢ë?°Ì3K¹¯Â? CD44v ÑyÙ¤¸¢ë?°Ì3K¹¯Â? CD44v Ñ=¨Ñ=?í&RNA T$QOoV'

5 U  º G 1 N J

"

27

!

+#a`¨¾¯­5U~³sG CD44v13 «xCZe^]gcVbf\i&±F:Rt
CGu¼+(CD44v13 |«xsC9A TE1"TE11"¡«xsC9A TE4 T§¢9>'RTqPCR"FACS(!
,(Ze^]gcVbf\i¦µFOQ"|«xs'TE1"TE11(H¡«xs'TE4(F¬q
9A~³5w9>'MTT assay"day-"p )*#*/(!7G·zoH"Liveor Dye
T¶2> FACS pFOQZe^]gcVbf\i¦µFOQ~³GnT©KE4?>
7C4P~³zoBHE6·zoB1R7C5}8S>!

-(Ze^]gcVbf\i.**uM C±G®¶FOQ TE1'CD44v13 |«xs("TE4'¡«xs(2;SL®¶FOR~³·zoGvT©K>'colony assay#Day+."-(!
7G,@G~³F:RvzoH"Ze^]gcVbf\iC±<S=SG·zoG½jB1R7C4P"®¶FORzo5}8S>!

>" ,2/.41+03-5%C:?<:'BE&()=A#*9D&@$)8;F76
SSZ!,2/.41+03-5 Cont!control,#CRISPR Cas9 []_dFOR CD44vKO a`¨¾¯­5U~³sG¹C"±F
:Rt°m+(CRISPR Cas9 []_dFOR CD44vKOTE1 3OI<GYi`h%gT¹9>'.(!
,(CD44vKOTE1 sHYi`h%gF¬q9"~³ªG¡lT©K>'MTT assay : day-"colony assay : day+.# p )*#*/(!
-(±FOQ CD44vKO sHYi`h%gF¬q9"~³G¡lT©K>'colony
assay : day+.#.(!
-#RNA [%XWi]T¶2> CD44vKO ~³sG´¸¤k¥«xp
CD44vKOTE1 sBH PI3KAkt signaling pathway M Ras signaling pathway EDCGu¼T©K>'/(!
.#±ºyG¨5U

G CD44v «xmr±º'mrº²$CDDP&/FU(F£{T|B1?>'0(!

9>»H CD44v1 C CD44v2 G«x5

28*0-,2/).1+3(?A"$!9=5%<#':6@8;7B&4>

1! CD44vKO 04#(,6%3$'5-2/-&+.7*)

1" CD44vKO 04#(,6& signaling pathway6 [ µ " L 0 T Q

29-! %&3*.)4(#,1"$/+0# CD44v 2''÷KUW"%w^sgúH>F$¿áK{ÐK¯ý=YF1Xbvfexq\pwdyHò¸ÎÀ¸Zîý?X;HKUW"Ãä6[©õKÖ?X»(LÔZ¶?;H6¶¨=YB!=VK"

CRISPRCas9 ceitKUX CD44v nh`]^k©õZý1B·GM";YPGKñ¦=YF1X"
bvfexq\pwdyL xCT ÿÈKUX ROS LÞ&Ñ5VSBV=YX­©õLÔZ±´?XHJCB!;YVLKUW"ò¸ÎÀ¸K¤1à

ÉZ¶?6[©õZéáH?Xµ"Í

!LûÉ6×=YB!=VK;L6[©õZéáH>Bµ"M"Ãä6[LQJV@Õ8LzÉ»(KûÉZ¶?;H6üÒ=YX!PB"5FU JI

6[ªKUXò¸ÎÀ¸LÔ6ñ¦=Y

F1X6îýKUXåÉÔ6ùÙG0X~ó "bvfexq\pwdyMì¬ý6¾J85D°çú
/&G{G0X;H5VlvhawrdcumyaúH>FûöH¢3X!>5>"§L in vitro L·
GM"bvfexq\pwdyîýKUXò¸ÎÀ¸L=VJXûÉL¤1»(MAYOI¤8J5CB;H5V"¥íLãßZÆRF18èþ60X!

§M"ºH>F|L*DLâZ£2üßG0X!(#ÃäÚs^eZý1B in vivo GLÓÂZæ?X!)#bvfexq\pwdy6 xCT LÿÈZ>F ROS LÞ&ZÑ?X;HZæ?X!*#bvfexq\pwdyUW#K ROS LÞ&ZÑ?X¥íZãß?X!Ï$¿²

H>FL}ÜE9GÃä6[ò¸µ"K49Xbvfexq\pwdyîýLûÉK?X_ojy
eZÝË>F17B1!
! $ # "
ã¹L¼Øêðëêò¸ÎL'®¡øÌÊ"ïNK÷L<±³WP>B«ÛôÇ6[½áµ"«ÛL}KÄUW%Å>Á:P?!
(&(&Tachimori Y, Ozawa S, Numasaki H, et al : Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus 13$(('*-")'(,#)&Ishimoto T, Nagano O, Yae T, et al : CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc%&and thereby promotes tumor growth. Cancer Cell 19$*.+''")'((#

8>;:@=7<?9A6MO02!GKC3J15HDNFIEP4BL

30)%Diehn M, Cho RW, Clarke MF : Therapeutic implications of the cancer stem cell hypothesis. Semin
Radiat Oncol 19#-..,!(&&/"*%Chen C, Zhao S, KaRNAd A, et al : The biology and role of CD44 in cancer progression : therapeutic implications. J Hematol Oncol 11#,*!(&'."+%Diehn M, Cho RW, Lobo NA, et al : Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458#-.&)!(&&/",%Sleire L, Skeie BS, Netland IA, et al : Drug repurposing : sulfasalazine sensitizes gliomas to gamma
knife radiosurgery by blocking cystine uptake through system Xc, leading to glutathione depletion. Oncogene 34#+/+'/!(&'+"-%Shitara K, Doi T, Nagano O, et al : Doseescalation study for the targeting of CD44v+ cancer stem
cells by sulfasalazine in patients with advanced gastric cancer$EPOC1205%. Gastric cancer 20#)*'/!(&'-".%Otsubo K, Nosaki K, Imamura CK, et al : Phase I study of salazosulfapyridine in combination withcisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer Sci 108#'.*)/!(&'-"/%Rebecca WO, Richard MA : Combined chemotherapy and radiotherapy$without surgery%compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev.
CD002092!(&&)"

$"#!*&(')+%! SÅNE+)ý4+*c³×EMD:!

"

?

¹

400¼

.

15

4

+

400¼

. 105

¿Ò$Õ%

105}ü)¿ÒTvqhz*

>+

10~

¨Trmj{cC¸>SÎ"Ü;>¤}T÷>¼"¡æ=QL=:),>Q*c>:",8ARûóTØR<É?D:!15R40¼.40ªOE"ªcN?`K@9@Mtw{pegpEMD:!XJ"CD-ROM"DVD-ROM øRo&nc0ãEJ[Sc"¸>Ã"msp7c8SÎ"ÈR<à_D:!

#=&SÊ&7)+*Tç+¼"7"#7TË+¼N±D:!

$Ö¼T·>Ö¼c>:"õB«ë~T CGS ë~N m"cm"mm"cm2"ml"l"dl"kg"g"mg QP
OEMD:!

% ¿ÒTÂ´}ÎSç?DNÞ8N9`BO"+¼\<c­G`Ï®Tpy&k{iu&r&c=@JÎR8EMD:!
&¨TáOEM/:JEXHd!¿Ò"ÕQPN/c?G`[SRTIS¹8EMD:!

' +T4+ïR>DaJ[SSYc9AMD:!4+ïS>¢ÇRT$­c(EMD:!
( +SÉ?1T½S];RùEMD:!
>+"ðÁ7T3ÔXNE"Ia}ÎT+ä,+et al,OEMD:!
¯+S±¾T Index Medicus Ç±RÅFMD:!
µ»SÏ®/>$­*ðÁ7%E+é7"µ»7"Ö"-Ö)ÙDþ­*ëª4SÏ®/>$­*ðÁ7%E+é7"É7).Á7*"""-"!ªÇ7"!ªî")ÙDþ
­*C

1*ô¥Fí"£§ Ì"ò

9"ä%S@2#O@2 7)12*%108-114"1870#

2*6ü'"ñêÝÿ"¶²

Ñ%°3SßÓì2#gfxl=^°3W)*)

Ð.*"è2""308'327"O@2À"ö"1872#

3*Umezawa H, Aoyagi T, Suda H, et al : Bestatin, an inhibitor of aminopepitidase B, produced by Actinomycetes. J. Antibiotics 29 :86-88"1865#)+úT"+TFZR,NTFX_"+<b_R,NV!

*

E+T?¹-TFZR-)åÍ-12-×Ú*-©|-<b_R-+-%-ÕSÛ8-ÕSÆR
¨c¦×EMD:!Õ<]U%RT+ïRÄ`Æ$R$­c(EMD:!

+¬:T½S];Q­c>:XG!
-#

,

((1#

((1*

((a

¨RT%ºc(E"%é"ðÁ7"Çâ"7" ¨5Ö"Õ%óÖc8EMD:!

#-&%()'#.!,$+*"%+*%®÷Ã60#U¶B$Bä$Ì

}0#îAÏ¶Bô:?BaO$#%C$Èö

6³#Óð¶B2Bä$³É

1ý#1¼b,-.0/"$>ÎÇ0#É¶B2Bä$@Ò#q&óf<Þ8$Eh¥#ÌP¶B2?BaO$oc¸üL#¬þ¶B2Bä$Ú 4à#ÌPÊ&VrÞ8$¨ò¥#Ë¶B2Bä$÷ðJNý#U¶B2Bä$ÍN)à#Ãv¶B2Bä$é% ¼Ô#ÌA¶B2Bä$ãÆ#¶u¶B2Bä$

LÉ

#PÊ¶B2Bä$û3®÷Ã60#U¶B$Bä$

3²

üà#PÊ¶B2Bä$#&C$A/ó·x0 #Ìî¶B2Bä$f@¤#Ä¶B2Bä$~É[x#Z×¶B2Bä$À¨Û#îAÏ¶B2Bä$×l»#U¶B§´íg2BaO$

%+*&

y
úÉ
Ë

ØI#¶uá&¤Þ.0/"$ì#óf<¶B2Bä$ºà#ÌP¶B2Bä$#Ìî¶Bm{TÞaO$Îð õ»#1¼2?¶B$t­¢»#îAÏ¶B2Bä$5 ¶#Ìî¶Bm{TÞaO$

É

ÁK#ÌPÊ&VrÞ8$xi

ùà#o¼2?¶B$¾É\6#U¶B2Bä$©7

Nø#]2K¶B2Bä$#'C$ö²40#;y¶B2Bä$X÷Ü#¶æ2?¶B$¡e

pÜ#y#2?¶B$oN|ñ#ÌP¶B2Bä$M

ãÜ#Ìî¶Bm{TÞaO$ÿ,90#ÐË¶B2Bä$¨ç

Ç0#Ìî¶B2Bä$÷²

7à#q&Þ8U,-.0/"$Îe¶Û#¶u¶B2Bä$¯É

n#Wð¶B2Bä$xQ

#N'è¶B2Bä$¹Ñ

#wï2?¶B$%+*'yðxHà#U¶B§´íg2BaO$
%+*(

¶¨

p#U¶B2Bä$÷à#ÌPÊ&VrÞ8$#(C$ªÉ

Yx#;y¶B2Bä$

6ð5dL#¿Ö¶B.2B^$

Es

3ß#q&,-.0/"aO$

!É
e

%+*)

ü#îAÏ¶B2Bä$µD#q&Þ8U,-.0/"$¯yF#Ä¶B2Bä$yÉ

6¥#óf<¶B2Bä$`y#)C$S#kË¶BeÙêÕ2BaO$Â[°#U¶B2Bä$o_¦#Wð¶B2Bä$ÅÚ(#Ga!G=B+ë.0/"$å¨*#1Ý¶B2Bä$!

»#ÌP¶B2?BaO$£à#]2K¶B2Bä$î²jÜ#¶u¶B2Bäâ±GaO«$

¥½#

-

"#zR2?¶B$@2?¶B$

&+*'"0!+$8,-.0/#%$'M%áÛ

&+*(

º*

q

|ÿ$ÜÕJ3Jü%

qá



åá

±:$ÕÕJòÅþõnY­%#È*Ù$^o8,-.0/#nY­%²Ø

GÅ$äZâ8dõ7%

sÀ

¦5$8õ73;.0/#%

Váu¾$ö²3FÕJ%Õ1:$-rBÕJ3Jü%Þ?$äZÕJ3Jü%!1

mí$On!OCJ;%.0/#%¡1 [5$äZÕJ3FJnY­%0Ó

pQ$b¥ÕJÅÔ's3JnY­%W"áÞ>$hCUªÕJ3Jü%e*=.$)3FÕJ%4 "¹$äZâ8dõ7%¢cÏ?$éãÕJ3Jü%áÛ¹Ù$äZÕJ@4òÅþnY­%áÛ

iÄ$NÆ3FÕJ%ÆáT÷$`SÕJ3Jü%ë1 ¾$ZâÕJ3Jü%,$vãÕJqñ$î3JnY­%$aÖÕJ3Jü%

3$ÜÕJ3Jü%\* µ$hCUªÕJ3Jü%8Åø÷$äZ®3FÕJ´CRõ.0/#%öA 7í$ÕÕJ3JüûÒOnYÉ%

Îá

E?$Ý

\

Õ»

xí$AÕJ3Jü%°±÷$Ë5o,-.0/#%§¿$åáJ>"l;ÅÕJ3Jü%w$¬àæÕJ3Jü%

ÕJ3Jü%¯³¹ô$éãÕJ}ÐFJnY.0/#%Eå?$ÕÕJòÅþõnY­%aÖ{ì$ºKÕJ3Jü%*«5$2Úo,-.0/#%å¤$2Úo,-.0/#%=0+?$ä(ÕJy_õnY­%~*$äZâ8dõ7%èÞ$vãÕJqñ$î3JnY­%ÄAß$Õú8Â¾õ.0/#%²* f$ÕÕJ3Jü%X""$(IçÕJ3Jü%t&$Ë5ÕJ3JüðOnYÉ%

Vá

BH$ºKÕJ3Jü%¨¸5$ãÕJ3JüûÒ£DnYÉ%Í1/9$äZÕJ3FJnY­%×Å$Zâú83FÕJ%A¼U$Õú8Â¾õ.0/#%¶áÃ@$hCUªÕJ3Jü%zåÁ$]3FÕJ%°Ì[x$~Ú3FÕJ%LáÙ$vãÕJqñ$î3JnY­%½ê0<$ZâÕJ3Jü%°nì$¨áÕJ3Jü%åÄÙ$äZÕJ3Jü%ØÌ6ô$ý43FÕJ%ÛÓ$*M%1ü

ké9&+*+

6ç$b¥ÕJ3Jü%ß$ý43FÕJ%$)M%?Ó

&+**

ÝÑ

ÛÓ

$(M%Aü

&+*)Ä÷$8-rBõ7j<õ.0/#%Êçø?$gÕJ3Jü%¿¹$ÕÕJòÅþõnY­%©$xÎÕJ3Jü%
lô$b¥ÕJÅÔ's3JnY­%
ß$82';ÅnY­%ù9l$äZâ8dõ7%ï·Ä$ö²3FÕJ%ÿ1

1Ï

D?$äZÕJ3Jü%ÇÌ

A$e*ÕJ3Jü%{$)3FÕJ%P9

$Õú8Â¾õ.0/#%$+M%4

Äó$åáJ>"l;ÅÕJ3Jü%&*)*§Ñ *#1Çj+,-/."i\$#*N$?Ñ

&**%vt#1èÃI3Ið$¸

Ø$#ÃÃI3Ið$«#ýl@'ÃI3Iðó3Ii\$K¸ 4ë#Z(õÃI3Ið$

BÖ

a

µÖ

þã#'+,-/."é6$

Çz#1Çj+,-/."$
ã#_3CÃI¼~3,-/."$

6! Ü#>ê'ÃI3Ið$|§%5#ÙÔÃI3Ið$

É¾

Öü

W#|Ç3CÃI$ÊÑQZ$#_3CÃI¼~3,-/."$¤"²T#ÕúÃI3Ið$y4[ü

tÆ#eâÃI3Ið$<Öoë#Õ]3CCÃI3Iðî½é6$®

ÏØ#]ÒÃI3Iðî½é6$¡w#Ð×ÃI3Ið$#Õ]Ò'cé6$öþ#1Çj+,-/."$#&%N$Þ" ¢#{¸3CÃI$
»

&**&

¿Ñ

}#ÙÔÃI3Ið$!Å¥ë#ÃÃIæ³òéi\$ÈÑÔÍZþ#ÔÃI3Ið$ÑÉ )5#©LÃIái\$Ó^

5f#Î]ÃI3Ið$ÉÔ¹#ýl@ÃI3Ið$©Í%0#û3CÃI$´¾

Â#bÃI³Àùn3Ii\$

H³;#ÕEÃI3Ið$k¨ß#'é6b+,-/."$

ÖüÿÆ#1Ç3CÃI$ºk

Qç#bÃI3Ið$

­Å

T#'

2Ö

ë#1Çj+,-/."i\$

Y

#&&N$

3,i\-/."$

S#bÃI³Àùn3Ii\$¸1#¨ÃI3Ið$d:¦ô#|Ç3CÃI$BÖ!¾t0#Õ]3CÃI$D"ø#RíÃI3Ið$/!

3#qÃI3Ið$ÑÉ-þ#Õ]Ò'cé6$

ô4

ZO#Õ]ÃI3Ið$ª

Ux#Ãì'°¬é-/."$

Ö9"#û3CÃIî½+,i\$¨ë#uÔÃIkä÷à3Ii\$%#Pi!Pi\$p#Ãó3CÃI$åÔ$#ÝüÃI3Ið$Û£#ýl@ÃI3Ið$q±#]Òì'3CÃI$#-Ü0#ýl@'ÃI3Ið$¶Äm#_j'+,-/."$

vß#'+,-/."É=é6$#&'N$Gk¨þ#ÌÃI3Ið$h¤)ß#ËÃI3Ið$

D¾

8Ü#ú&i\é6$XÈ

g#!f2+,-/."$!ü

2ç#ÃÃIæ³òéi\î½é6$

MN

5#úEØÃI3Iðî½Pi\·$&**'`7 -ç#]ÒÃI3Ið$

&**(

Ö

V³#Ãó3CÃI$6ï T$#aÄÃI+,i\$·JÑ¢#©LÃI3Ið$Ó4

Ú- ¨$#Õ]3CCÃI3Ið$´¾

r#ÕEÃI3Ið$A

YFÂ¨#ýl@ÃI3IðéÁ¯ni\·$Ã7

Â+#?ÃI3Ið$s#aÄÃI3Ið$0ð .#ñÔj'3CÃI$¨z#Õ]Ò'cé6$
#Ãì'°¬é-/."$

%++&

&

nL#Á23.417FÓO$-ç¼#jM[¥ÓO7Oÿ$#%&R$gs2#¯JÓOýÌ+£ø;$¬Ù

I#Wo!Wo`ª$q

ó#ßaÓO7Oÿ$>ãÀ¯#aåüB7FÓO$þ

Yï#-MìÓO7OÿýÌWo`Å$ÕÍæãE¯#éaÓO7Oÿ$

u8

JJ#éaåBfø;$ûã

Tú#cpB,-/40"o`ª$ÛÍb9#éa7FFÓO7Oÿ$Qã>##Wo!WCOD)/40"$$Aà#ÓüB»µø/40"$$A³S#aåÓO7Oÿ$.

«[#é-ÓODG7Oo`ª$]ã°ï#3tBÓO7OÿøÑºwo`Å$Ê<

iK#Wo!WCOD)/40"$

ÙãL#B,-/40"Û?ø;$#%'R$Í½ð#aåÓO7Oÿ$AãÈ#e¡ÓO¿Ð,w7Oo`ª$ÄPÀ9#é-ÓO7Oÿ$\Ø]#/7FÓO7Oÿ$

%++'

%++(

#JGpB7FÓO$¬; ×÷#-MìÓO7Oÿ$·0

á#_7FÓO$¾6 r#dÔÓO,-o`ª$ãÛn9#±QÓO7Oÿ$

Þ

×

±ã

Ò#©âëÓO7Oÿ$ùzì»#3tBÓO7Oÿ$°:#ÚòÓOF®7Ol$

ê0 ¢9#Æ?p,-/40"$;P¯ú#Wo!Wo`ª$



]ã

A0

§

#3tBÓO7OÿýÌø;$#ç7FÓO$­#3tBBÓO7Oÿ"7Oo`ª$#%(R$êÜõt#Bhø;$èããÛ

#@ùBÓO7Oÿ$yú#~çÓOsô(ñ7Oo`ª$

H8

#ÓüB»µø/40"$

É#éaåBfø;$vê¤Ë#ßaÓO¿!}Oo`/40"$ê|#ßaÓO7Oÿ$ã

S#jM[¥ÓO7Oÿ$ÛÍ

#ÝÓO7DZ¦ÖXÓOÿ$êã¨#aåÓOÓO;7Oo`F$

16½[#dÔÓO,-o`ª$

U9ó#7FÓO7Oÿ$²

5I#éaÓO7FOo`ª$;Ç

R#e¡ÓOÓO;¶AOo`F$ÃÇ

#ÓüB»µø/40"$

JO íú#e¡ÓO¿Ð,w7Oo`ª$
%++)

<8

#%)R$6é%++*#aåÓO7Oo`F$

bx#^C%ÓO7Oÿ$ÓÇú#ÚòÓOF®7Ol$¬P k8#7FÓOm=7Oo`ÿ7$8½÷#VÂäEø;$ê :#é-ÓODG7Oo`ª$

:

ÏI#

·0

Õ

*9#Wo!WCOD)/40"$

×7FÓO$

nH#éaÓO7FOo`ª$Î@öJI#´îÇpB,-/40"$°Í'~#B,-/40"Û?ø;$N_¸=#I7FÓO7Oÿ$K »µ#~çÓO7Oÿ$]Í¯÷#^C%ÓO¿4FOo`ª$ÂN Ý|#B,-/40"o`ª$´'{9#/7FÓO$ãÛJú#e¡ÓO7Oÿ$#%*R$¹u©9#Ó"7FÓO7Oÿ$DÓ#5×p,-/40"o`ª$

&**(

Óp

¢G#?s?¾=@N$$#&(P$ÚÂo
0;
&**)

¨

#&)P$}pç

­#ÍÍN:N$$¯#Á=m+/364"$

7â

ß¾#Sl!Sl_¥$

5#è/ÍNÍN=:Njl_G$®õ#?+/364"ÚBû=$:#8Â:GÍN$:#è`ÍNÍN=:Njl_G$>7

Aõ#Íÿ?º¶û364"$

é

«#

ª#?û=g+/364"$

1:GÍN:N$$Ñ

àï#Í?ÍN:N$$Úç4Â

x<#è`ÍN:N$$äôo¼ü#è`:GGÍNíRl_¥$÷½ú#:GÍN$ýó

±H#7Øm+/364"$

ÃÒ¢#á>-.,Å×¥:Nl_¥$9ns¼#c:GÍN:N$$Í°

lî#èJÍN:N$$

É;

§#iJ[

ÍN:N$$*#ÍN:N$$8 Aþ#Sl!SDNB-364"$
&***

;°

¢ú#ÍÍNÍN=$#&*P$ÍÎ

#wçÍNoö,ð:Nl_¥$FIÒ9|#wçÍN:N$$

H°:#iJ[ ÍN:N$ÀÕ:GNl_¥$´K<<#`åÍN1052l_¥$âÚ¤#/JêÍN:N$$

}

ß#

æâ

¼Ç#²OÍN:N$$7â

»#è`:GGÍNíRl_¥$

3Ì

¬X#`åÍN:N$$uâÜ#fÏÍN+/l_¥$³I ]A#U!ÍN:N$$\Y

ÐQ#I:GÍN$C7½A#eWÍN:N$$

ãL
'%%%

;°

1:GÍN$##gÍN¾Ë.q:Nl_¥$¼#fÏÍN:N$$#'%P$H7 'þ#?h2û=$]+ ë#iJ[

ÍN:N$$¨¿';#:GÍNÍ^:B364"$

õ#fÏÍN+/l_¥$âÚ{<#`åÍNÍN=$Ú7 #gÍNÍN=$ø7

bþ#Sl!Sl_¥$

%2

®É

é

'%%&

N#è/ÍNFF:Nl_¥$tEï#wçÍNoö,ð:Nl_¥$\âØï#è`:GÍN$

Ê#Sl!Sl_¥$#'&P$)7 rÖ#gÍNÍN=$5#ÙòÍNE©:Nj$\Â#ÍÍNÍN=$è

¢'#iJ[

ÍN:N$$¨D ú#dm?+/364"$KÝaTw#I:GÍN$}a£#è`ÍN:N$"Èû=$âo

y#è`ÍN:GNl_¥$d6

ÛC#/JêÍNÍN=$Þy·#}Øm?ÚBû=$ÚçM#]@(ÍN:N$$

7ç
ÉL
¹
'%%'

µì6´>#è`:GGÍN:NÆ~l_G$â

õ#ÍÍNù¾&ûl_¥$Äz#è`¦:GÍNñµk364"$®ª±#gÍN:BZ¡ÔVÍN$$

2

õv#

Aé

Ä:#I:GÍN$

1:GÍN$¸#?+/364"l_¥$x¢#/JêÍNÍN=$&%%&

M/ ªV#¬ßçÏK9Kû$#&&N$C&%%'À8#Æ9HÏK$`&#dÐÏK/2o]­$!ÛÂ#Ïø7¿¼ö354"$´* µì#§ÏK9Kû$#&'N$»à&%%(®/J#ÖðÏK<¯9Kl$ëshî#Ïø7¿¼ö354"$!:

÷#Ro!Ro]­$)|

2#jAY¨ÏK9Kû${#äÏKö>$I/

Gþ#äÏKÏK>9KÉo]H$

hî#Ro!RFK9%354"$=#e£ÏKö>$þh#_âÏK9Kû$×ä

uÑ ?[#7Òp/2354"$ÁºÂ¢#e£ÏKÄÎ'z9Ko]­$*gÑ±,#7¿;99354"$ïÙ#8;ÏK9Kû$

Þ~#å_ÏK9KûúËö>$ãE

#dÐÏKÏK>$"- O÷#dÐÏK9KûúËö>$òs

=#b9HÏK$ØÑÆ}W#+uEÏK9KûúËö>$?Ä

ÏX#Ï7ÏKÏK>$;·=#å(ÏK9Kû$í/Jî#Ï7ÏKÏK>$Ç* ¤=#ÏÏKÏK>$:´

h#ÒÏK9Kû$Ïå,#Ïø7¿¼ö354"$

§#å_â7fö>$

Bà ,[#Ïø7$#nÉ99354"$

ÕêÊ#»w99354"$

ýD ?.#ÿv9HÏK$æ:Â¼#å_99354"$<*´/

Ãµ#Ïø7¿¼ö354"$^¦

è#cU×BaûP354"$®;

#é:p79HÏK$=#ØÏK9Kû!KûúËö>$#&+N$ñEsn#Ro!1,ö>$@²õ#í*9HÏK$Ý#S¡9HÏK9Kû$«#jAY¨ÏK9Kû$Å#ip7×Bö>$°#7/2354"×Bö>$Ú+¥==#å_ÏK9KûúËö>$µÜ#å_â7fö>$¸Ó

4î#äÏK9Kû!KûúËö>$q²:#dÐÏK9KûúËö>$/

6u#7/2354"×Bö>$LÓ

Z#e£ÏKÏK>$ôÑA¢#+uEÏK9Kû$Õä¶~#Ro!1,ö>$³Ì ##7/2354"åö>$r3:#dÐ9HÏK$Z

áC ±õ#(6ÏK9Kû$#&,N$¸Ó 4î#äÏKÏK>$&%%-Âó#jAY¨ÏK9Kû$¾

#&*N$Íà

&%%,wà

I/ ì#5ÏK9Kû$#&)N$@ã&%%+

j=#å_â7fö>$

tQ

à×

&%%*

`

Èµ#å_ÏK9Kû$#&(N$Ã\&%%)®Ç?>#(6ÏKåö>$Ô=#dÐÏKÏK>$©½0.1#e£ÏKö>$#&-N$!à
ØÑÆ

kY#TùÏKÏK>$*à/¹y#ÖðÏKÏK>$×º

Âì#Ï99354"$

m#å_ÏKÏK>$üûx>#å_â7fö>$\à&#jAY¨ÏK0Kû$
ó#ÏÏKÏK>$

'%&%

ê

¾#Ô8HÔP$ÈÊ

Kñ#íCv>8HÔP$­¼;#É:ÔPÔP<$×

M#HIv>8HÔP$ßæ#pJ\«ÔP8P#$

ëy\ñ#ÔÔPÔP<$~ H3#WÿÔP8P#$

~?;#ÔÔPÔP<8Pqu`H$]Ú>#pJ\«ÔP8P#$

Ï;#lòÔPÔP<8Pqu`H$ë×HÄ#>ú<XÔ8B243"$, Ä0#Ôþ>Â¾ú243"$_æ

#ÝÔPú<$_æ\#éÔPyö)¡Ì8HPu`°$x9

èù#ê*ÔPú<$F

r#*=ÔP8P#$
QÆ

Hô#V£8HÔP8P#$

Y#-1u`M60ú<$ë#+8HÔP$

L2 Ä#5Ùv-1243"ÛAú<$d©ä#Ôþ>Â¾ú243"$

×C,S²#êaçsÝ¥8B243"u`°$µ2 N=#pJ\«ÔPú<$Ò¸?¦#iÖÔPÃnOH$9¸

m#ÙÔPc:u`#$D?#j§ÔPú<$#((R$Jt#.zE>ÔPÔP<8Pu`H$*eÊä#ÔÔPÔP<8Pqu`H$æãF#^?&ÔP8P#$

é

1ü#iÖ8HÔPÎ8Pu`°$¤Òb#(%R$³'%&&#(&R$â

'%&'=, ©@#g8HÔP$#('R$±Æ

'%&(

'%&)

2F

P#Ôþ>Â¾ú243"$±

78#pJ\«ÔP8P#$

Y#-1u`M60ú<$-y\ñ#¯åìÔP8P#$»#ê*ÔPGE8Pu`°$×î

oL#ÙÔP8P#!Ðú<$ø#Ôþ>Â¾ú243"$ô^#Ô>ÔPÔP<8Pu`H$ýæÞ¾#Bû>ÔPÔP<8Pu`H$ÛÍï×Ó¿#êaÔP8P#!Ðú<$Ý×ÊÔ;G#${v>./0ú<$È

ôK#*=ÔP8P#$

÷4<#pJ\«ÔP8P#$

õÈ#hZÔP8P#$#(*R$=9 I%#TÆ8HÔP$ÜÔA#-1u`M60ú<$îë>f#ÇCv>ÇC-1243"$Ææ®#ÔÔP8P#!Ðú<$D9}#k,ÔPÔP<Å/HPu`#$Àé

H#ÔÔPÔP<8Pqu`H$±¶[´#êaÔP8HPu`°!Ðú<$6à#êaÔPÔP<8Pqu`H$#(+R$ó'%&,#|8B243"!Û-1243"$

Ud

d

'%&+

#pJ\«ÔP8P#$

4º ¬(#.zE>ÔPú<$#()R$±Æ'%&*¼¦#${v>-1243"$

#açþ>8HÔP$#j§ÔPÔP<$ÁÒmðG#Ôþ>Â¾ú243"$Õ~¨#ÔÔP8Pqu`H$ë'¿#Ô8HÔP!Ðú<$Íæ

A#ëæ's@ÅÔP$¢áÑ#-1u`M60ú<$ªæ 7#Ô-1243"$#(,R$½æ
ò¹}G#.zEÔP8P#!Ðú<$·#k,ÔPÔP<Å/HPu`#$Ëð#iÖÔPÔP<85'sPÎu`H$

4w"Ø#íCv>8HÔP$6Sx¨D2KH+/_+)+l*, Zw+)+l+) s

"

s

!

#

q[u

6S|^x¨ngu o a 4£3tQ<E\dC4`33=:G;!
')+-&((.) irjep)&*/&TUVW+1,-*.&.,0+©$(+%

Zw~ XkZw¡D¥DY2O3ER¢@"ycb35BO
 CL>?Jy#;O8AE" §@IMP=tR
7"v{4LF}{Dm¦D]CBNG;D@"¤I
zDhRfI?\93!